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  Introduction 
   
1. INTRODUCTION 
           Analytical chemistry has played a major role in the changes facing the 
pharmaceutical industry today. Traditionally viewed as a service organization, the 
analytical department has become a significant parameter in the drug development 
process. Indeed, the demand for analytical data has become a critical path activity for 
selection of molecule for full development. The pharmaceutical analysis plays a major 
role in assuring, identity, safety, efficacy, purity and quality of a drug product. The 
need for pharmaceutical analysis is driven largely by regulatory requirements. (Satinder 
Ahuja, 2005; Takeru Higuchi, 2002)  
 
The discipline of analytical chemistry consists of, 
1.Qualitative analysis: - which reveals the identity of the element and compound   
in a sample. (Alexeyev, 1994) 
2.Quantitative analysis: - indicate the amount of individual element or compound 
present in sample. 
 
1.1. Methods of quantitative analysis   ( Devaraj  Rao, 2004)  
 
                        Under the quantitative analysis, the procedures of quantitative analytical 
chemistry are applied to the analysis of material used in pharmaceuticals. 
 
                       There are various methods for quantitative analysis of pharmaceuticals. 
In general the components are related characteristically to some physical property and 
on the basis of that, the quantity is estimated. They are classified into the following 
types: 
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1.1.1 Chemical Methods 
1.1.1.1 Volumetric or Titrimetric  
                        a. Acid-base or Neutralizations Titrations 
                        b. Oxidation-Redution or  Redox titrations 
                        c. Precipitation titration 
                        d. Complexometric titrations 
                        e. Non-aqueous titrations    
1.1.1.2. Gravimetric 
1.1.1.3. Geometric 
 1.1.2. Instrumental or physico-chemical methods 
          Instrumental methods are based on the relation between the content and 
corresponding physical or physico-chemical properties of the system being analyzed 
PHYSICAL PROPERTY 
MEASURED 
INSTRUMENTAL METHODS BASED 
ON MEASUREMENT OF PROPERTY 
Absorption radiation 
Emission of radiation 
Rotation of radiation 
Electrical Potential 
Electrical conductance 
Electrical current 
Thermal properties   
Spectrophotometry (x-ray, UV, Visible, IR) 
NMR. 
Fluorimetry, Flame photometry 
Polarimetry, ORD, CD. 
Potentiometry, Chrono-potentiometry 
Conductometry. 
Polarography, Amperometry. 
DTA, DSC etc. 
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1.1.2.1. Chromatographic methods 
 i)  Thin layer chromatography (TLC) 
 ii)  Paper chromatography  
 iii) Column chromatography  
 iv) Gas chromatography 
 v)  High Performance Liquid Chromatography (HPLC) 
1.1.2.2. Hyphenated techniques 
 i) GC-MS (Gas chromatography – Mass spectrometry) 
 ii) LC-MS (Liquid chromatography – Mass spectrometry) 
 iii)GC-IR (Gas chromatography – Infrared spectroscopy) 
 iv) ICP-MS (Inductively coupled plasma – Mass spectrometry) 
1.1.3. Microbiological methods 
1.1.4. Biological methods 
 Factors affecting the choice of analytical methods (Mendham, 2002) 
  The type of analysis required. 
  Problem arising from the nature of the material 
  Possible interference from components of the material other than those of  
interest. 
  The concentration range which needs to be investigated. 
  The accuracy required. 
  The facilities available. 
  The time required for complete analysis. 
  Similar type of analysis performed.   
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1.2. UV- SPECTROSCOPY (Atherden, 1996; Satinder Ahuja, 2005) 
  UV-absorptions are mainly electronic in nature and are associated with 
resonating structure in the molecule. It involves the measurement of the amount of UV 
(200-400nm) radiation absorbed by a substance in solution.  UV - absorption is an 
essential tool for qualitative and quantitative determination of a single component drug 
or isolated extract. The UV quantitative determination generally performed in solution 
is based on the Beer-Lambert’s law.     .   
          UV region of the electromagnetic spectrum is frequently subdivided into 
far vacuum UV region (10 – 200 nm) and near UV region (200 – 400 nm). The 
utilization of near UV absorption spectra as an analytical tool has increased in recent 
years, because of commercial availability of the UV spectrophotometers which are 
recording the spectrum in this region.   
         Quantitative determination of single drug substance in a nonchromophoric 
solvent such as aqueous or alcohol solution may be a good application for the UV 
method.  In a   method development study, solubility, stability studies are performed 
with the UV technique. UV is extensively used for HPLC detection. 
1.3. VISIBLE SPECTROPHOTOMETRY  
       (Mendham, 2002; Satinder Ahuja, 2005) 
                      Visible spectrometry is identical to UV spectrometry, with the exception 
of the wavelength, which are ranges from 400-800 nm. Most drug substances are 
colorless; however, a color product may be formed with specific agent, as a result of 
chemical reaction. Quantitative determination of the colored compound is based on  
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this principle for drug assay. This technique was used quite extensively during the early 
stages of pharmaceutical analysis in the years of 1950 to 1960. 
        Advantages of the colorimetric method include the following: 
1. Inexpensive equipment(colorimeter) used for analysis(useful for field 
test) 
2. Selective detection of a colored compound formed. (Selective chemical 
reagent reacting with the compound of interest alone, e.g. Functional 
group analysis). 
3. Enhanced detection sensitivity for compounds with low UV-
characteristics. 
Another method of forming a color compound (subsequently separated 
by extraction) is the dye-salt method. In an ion pair reaction, a colored 
complex of the drug with a dye of opposite polarity is formed which is 
extracted into the organic layer and determined colorimetrically.  
Colorimetric analysis should satisfy following criteria.   
1. The color reaction should be specific. 
2. Proportionality change between color and concentration. 
3. Color should be stable to permit an accurate reading 
4. Reproducible results should be notified. 
5. Solution must be free from precipitate. 
6. The color reaction should be highly sensitive.   
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1.3.1. The Absorption laws (Sharma, 1980) 
 There are two laws which govern the absorption of light by the molecules. 
These are, 
i . Beer’s law 
ii. Lambert’s law 
i. Beer’s law 
 This law states that, when a beam of monochromatic radiation is passed through 
a solution of an absorbing substance, the rate of decrease in intensity of transmitted 
radiation with thickness of the absorbing solution is directly proportional to the 
intensity of incident radiation as well as the concentration of the solution. 
ii. Lambert’s law   
 It states that, when a beam of monochromatic radiation passes through a 
homogenous absorbing medium, the rate of decrease in intensity of transmitted 
radiation with thickness of absorbing medium is directly proportional to the intensity of 
the incident radiation. 
 1.3.2. Choice of solvent  (Robert, 2006; Sharma, 2000) 
            The choice of solvent that is used in an assay in the ultraviolet-visible region is 
based upon two criteria. First, of course, the sample must be soluble in the solvent; the 
solvent must be transparent to the radiation of the wavelength in which the study is 
conducted. 
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            The solvents can be used at wavelengths that are longer than the cutoff 
wavelength. A most suitable solvent is the one which doesn’t itself absorb in the region 
under investigation. A dilute solution of the sample is always prepared for the spectral 
analysis. The absorbance of solvents should be checked before use, because the 
presence of small amounts of impurity may give rise to appreciable absorption in   the 
sample. For ultra violet and visible spectroscopy, ethanol, water and cyclohexane serve 
as the best solvents.   
1.3.3. Detectors (Willard, 1986) 
           A detector is a transducer, converting electro magnetic radiation into an electron 
flow and subsequently into a current flow or voltage in the read out circuit. Many times 
the photo current requires amplification, particularly when measuring low levels of 
radiant energy. There are single element detectors such as solid state photo diodes, 
photo emissive tubes and photo multiplier tubes and multiple element detectors such as 
solid state array detectors. Important characteristics of any type of detector are spectral 
sensitivity, wave length response, gain and response time. 
1.3.4. Quantitative analysis  (Beckett and stenlake, 2002) 
           The assay of an absorbing substance may be quickly carried out by preparing a 
solution in a transparent solvent and measuring its absorbance at a suitable wavelength. 
The wavelength normally selected is a wavelength of maximum absorption (λmax), 
where small errors in setting the wavelength scale have little effects on the measured 
absorbance. 
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a. Assay of substances in single component samples 
          Absorption spectroscopy is one of the most useful tools available to the chemist 
for quantitative analysis. The most important characteristics of photometric and 
spectrophotometric methods are high selectivity and ease of convenience. Quantitative 
analysis (assay of an absorbing substance) can be done using following methods. 
- Use of A (1%, 1cm) values 
- Use of calibration graph (multiple standard methods) 
- By single or double point standardization method. 
i. Use of A (1%, 1cm) values 
 This method can be used for estimation of drug from formulations or raw 
material, when reference standard not available. The use of standard A (1%, 1cm) value 
avoids the need to prepare a standard solution of the reference substance in order to 
determine its absorption. 
ii. Use of calibration graph 
 In this method, a calibration curve is plotted using concentration (X-axis) Vs 
absorbance (Y-axis) with the value of 5 or more standard solutions. A straight line is 
drawn   through maximum number of points. This method is called as line of best fit. 
By interpolating the absorbance of the sample solution and using the calibration curve, 
the concentration of the drug amount and percentage purity can be calculated.  
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iii. Single or double point standardization 
          The procedure involves the measurement of the absorbance of a sample solution 
and standard solution. The standard and the sample solution are prepared in similar 
manner; ideally the concentration of the standard solution should be close to that of the 
sample solution. The concentration of the substance in the sample is calculated using 
following formula. 
                                    Ctest = Atest / Astd × Cstd 
Where, 
Ctest and Cstd are the concentration of the sample and standard solutions 
respectively.  
Atest and Astd are the absorbance of the sample and standard solutions 
respectively. 
 In double point standardization, the concentration of one of the standard 
solution is greater than that of the sample, while the other standard solution has a lower 
concentration than the sample solution. The concentration of the substance in the 
sample solution is given by  
                                  (Atest – Astd1)(Cstd1-Cstd2) +Cstd1(Astd1-Astd2) 
                      Ctest=              
                                Astd1-Astd2 
Where, 
Cstd is the concentration of the   standard solution.  
Atest and Astd are the absorbance of the sample and standard solution 
respectively. 
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std1 and std2 are the more concentrated standard and less concentrated standard 
respectively. 
b. Assay of substances in multi component samples 
             The spectrophotometric assay of drugs rarely involves the measurement of 
absorbance of samples containing only one absorbing component. The pharmaceutical 
analyst frequently encounters the situation, where the concentration of one or more 
substances is required in samples known to contain other absorbing substances which 
potentially interfere in the assay. Unwanted absorption from these sources is termed 
irrelevant absorption and if not removed, imparts systematic errors to the assay of the 
drug in the sample.  A number of modifications to the simple spectrophotometric 
procedure for single-component samples is available to the analyst, which may 
eliminate certain sources of interferences and permit the accurate determination of one 
or all of the absorbing components. 
            The basis of all the spectrophotometric technique for multicomponent samples 
is the property that at all wavelengths, 
a) The absorbance of a solution is the sum of absorbances of the individual 
components; or 
b) The measured absorbance is the difference between the total absorbance 
of the solution in the sample cell & that of the solution in the reference 
(blank) cell. 
The determination of the multi-component samples can be done by using the following 
methods:  
• Assay of a single-component sample 
• Assay using absorbance corrected for interference 
10 
   
• Assay after solvent extraction of the sample 
       Simultaneous equations method 
       Absorbance ratio method (Q-Analysis) 
       Geometric correction method 
       Orthogonal polynomial method 
       Difference spectrophotometry 
       Derivative spectrophometry 
       Chemical derivatisation 
 
i. Simultaneous equation method 
If a sample contains two, absorbing drugs (X and Y) each of which absorbs at 
the λmax of the other as shown in Fig, it may be possible to determine both drugs by the 
technique of simultaneous equations (Vierodt’s method).   
  
 The information required is:  
a)  the  absorptivities  of X at λ1 and λ2, ax1 and ax2, respectively 
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(b) the  absorptivities of Y at λ1 and λ2, ay1 and ay2, respectively  
(c) the absorbance of the diluted sample at λ1 and λ2, A1 and A2  respectively. 
Let Cx and Cy, be the concentrations of X and Y respectively in the diluted sample. 
Two equations are constructed based upon the fact that at λ1 and λ2 the 
absorbance of the mixture is the sum of the individual absorbance’s of x and y, 
                      At  λ1 A1 = ax1bcx + ay1bcy    -------- (1)                                             
                      At λ2 A2 = ax2bcx + ay2bcy   --------- (2)                                                                
For measurement in 1cm cells, b = 1. 
Rearrange eq.(2) 
                                               A2– ax2cx 
                                     Cy =  
                ay2 
  
Substituting for Cy in eq,(1) and rearranging gives 
             A2ay1 – A1ay2         
Cx=  
ax2ay1—ax1ay2         ---------(3) 
                                                                 
                        
              and  
                                A2ay1 – A1ay2         
Cy=  
      ax2ay1—ax1ay2         ---------(4) 
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As an exercise you should derive modified equations containing a symbol (b) 
for path length, for application in situations where A1, and A2 are measured in cells 
other than  1 cm path length. 
             A2/A1                       ay2/ay1 
            ax2/ax1                    and      A2/A1  
Criteria for obtaining maximum precision, based upon absorbance ratios, have 
been suggested that place limits on the relative concentrations of the components of the 
mixture. The criteria are that the ratios should lie outside the range 0.1-2.0 for the 
precise determination of Y and X respectively. These criteria are satisfied only when 
the λmax of the two components are reasonably dissimilar. An additional criterion is that 
the two components do not interact chemically, thereby negating the initial assumption 
that the total absorbance is the sum of the individual absorbance. The additivity of the 
absorbance should always be confirmed in the development of a new application of this 
technique. The British Pharmacopoeia assay of quinine-related alkaloids and 
cinchonine-related alkaloids in cinchona bark is based, upon this technique. 
ii. Absorbance ratio method 
           The absorbance ratio method is a modification of the simultaneous equations 
procedure. It depends on the property that, for a substance which obeys Beer’s law at 
all wavelengths, the ratio of absorbances at any two wavelengths is a constant value 
independent of concentration or pathlength. For example, two different dilutions of the 
same substance give the same absorbance ratio A1/A2, 2.0. In the USP, this ratio is 
referred to as a Q value. The British Pharmacopoeia also uses a ratio of absorbances at 
specified wavelengths in certain confirmatory tests of identity. For example,  
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Cyanocobalamin exhibits three λmax at 278 nm, 361 nm and 550 nm. The A360/A550 is 
required to be 3.30 ± 0.15 and the A361/A278 to be 1.79 ± 0.09. 
iii. Geometric correction method 
             A number of mathematical correction procedures have been developed which 
reduce or eliminate the background irrelevant absorption that may be present in 
samples of biological origin. The simplest of these procedures is the three-point 
geometric procedure, which may be applied if the irrelevant absorption is linear at the 
three wavelengths selected. 
iv. Orthogonal polynomial method 
            The technique of orthogonal polynomials is another mathematical correction 
procedure which involves more complex calculations than the three –point correction 
procedure. The basis of the method is that an absorption spectrum may be represented 
in terms of orthogonal functions as follows: 
 A(λ) = p0P0(λ) + p1P1(λ) + p2P2(λ) . . . pnPn(λ) 
             Where A denotes the absorbance at wavelength λ belonging to a set of n + 1 
equally spaced wavelengths at which the orthogonal polynomials, P0(λ), P1(λ), P2(λ) . . . 
Pn(λ) are each defined. 
v. Area under the curve method 
              From the spectra obtained for calculating the simultaneous equation, the area 
under the curve were selected at a particular wavelength range for both the drugs were 
each drug  have its absorption. The “X” values of the drugs were determined at the 
selected AUC range. The “X” value is the ratio of area under the curve at the selected 
wavelength range with the concentration of the component in mg/ml. These “X” values 
were the mean of six independent determinations. A set of two simultaneous  
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equations were obtained by using mean “X” values. And further calculations are carried 
out to obtain the concentration of each drug present in the sample. 
vi. Derivative spectrophotometry 
          Derivative spectrophotometry involves the conversion of a normal spectrum to its 
first, second or higher derivative spectrum. The transformations that occur in the 
derivative spectra are understood by reference to a Gaussian band which represents an 
ideal absorption band. In the context of derivative spectrophotometry, the normal 
absorption spectrum is referred to as the fundamental, zeroth order or D° spectrum. 
          The first derivative (D1) spectrum is a plot of the ratio of change of absorbance   
with wavelength against wavelength, i.e. a plot of the slope of the fundamental 
spectrum against wavelength or a plot of dA/dλ Vs λ. At λ2 and λ4, the maximum 
positive and maximum negative slope respectively in the D°. Spectrums correspond 
with maximum and a minimum respectively in the D1 spectrum. The λmax at λ3 is a 
wavelength of zero slope and gives dA/d λ 0, i.e. a cross-over point, in the D1. 
Spectrum. 
 
         The zeroth (a), first (b) and second (c) derivative spectra of a Gaussian band.The 
second derivative (D2) spectrum is a plot of the curvature of the D° spectrum against 
wavelength or a plot of d2A/dλ2 Vs λ. The maximum negative curvature at λ3 in the D° 
spectrum gives a minimum in the D2 spectrum, and at λ1 and λ5 the maximum positive 
curvature in the D° spectrum gives two small maxima called ‘satellite’ bands in the D2 
spectrum. At λ2 and λ4 the wavelengths of maximum slope and zero curvature in the D° 
spectrum correspond with cross-over points in the D2 spectrum. 
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In summary, the first derivative spectrum of an absorption band is characterised 
by a maximum, a minimum, and a cross-over point at the λmax of the absorption band. 
The-second derivative spectrum is characterized by two satellite maxima and an 
inverted band of which the minimum corresponds to the λmax of the fundamental band. 
As an exercise, you should construct third and fourth derivative spectra (i.e. plots of 
d3A/d λ3 and d4A/d λ4 respectively against wavelength) of the fundamental spectrum. 
These spectral transformations confer two principal advantages on derivative 
spectrophotometry. Firstly, an even order spectrum is of narrower spectral bandwidth 
than its fundamental spectrum. A derivative spectrum therefore shows better resolution 
of overlapping bands than the fundamental spectrum and may permit the accurate 
determination of the λmax of the individual bands. Secondly, derivative 
spectrophotometry discriminates in favors of substances of narrow spectral bandwidth 
against broad bandwidth substances. This is because ‘the derivative amplitude (D), i.e. 
the distance from a maximum to a minimum, is inversely proportional to the 
fundamental spectral bandwidth (14’) raised to the power (n) of the derivative order.  
Thus,                         D α ( 1/W )n 
Consequently, substances of narrow spectral bandwidth display larger 
derivative amplitudes than those of broad bandwidth substances. 
(a) The individual spectra of two components X and Y in admixture and their 
combined spectrum (b) The second derivative spectrum of the mixture showing 
improved resolution of the individual bands. 
These advantages of derivative spectrophotometry, enhanced resolution and 
bandwidth discrimination, permit the selective determination of certain absorbing 
substances in samples in which non-specific interference may prohibit the application  
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of simple spectrophotometeric methods. For example, benzenoid drugs such as 
Ephedrine Hydrochloride, displaying fine structure of narrow spectral bandwidth in the 
region 240—270 nm, are both weakly absorbing (A about 15) and formulated at a 
relatively low dose in solid dosage preparations (typically 1—50 mg/ unit dose). The 
high excipient/drug ratio and high sample weight required for the assay may introduce 
into simple spectrophotometric procedures serious irrelevant absorption from the 
formulation excipients. Second derivative spectrophotometry discriminates in favour of 
the narrow bands of the fine structure of the benzenoid drugs and eliminates the broad 
band absorption of the excipients. All the amplitudes in the derivative spectrum are 
proportional’ to the concentration of the analyte, provided that Beer’s Law is obeyed by 
the fundamental spectrum. The measured value in a quantitative assay is the largest 
amplitude that is unaffected by the presence of other, absorbing components of the 
sample. 
The enhanced resolution and bandwidth discrimination, increases with 
increasing derivative order. However, it is also found that the concomitant increase in 
electronic noise. Inherent in the generation of the higher order spectra, and the 
consequent reduction of the signal-to-noise ratio, place serious practical limitations on 
the higher order spectra. 
1.4. HIGH PERFORMANCE LIQUID CHROMATOGRAPHY             
         (Satinder Ahuja, 2005; Lloyd, 1997)      
          HPLC has contributed many successes in quality control and in product 
development in the pharmaceutical industry. The UV detector coupling with HPLC 
equipment is the most important analytical instrument for quality control, quality 
assurance and in-process control in pharmaceutical analysis. HPLC is a basic and   
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reliable analytical tool for analytical study because of the high resolution capacity, 
accuracy and reproducibility of the equipment. 
          High performance liquid chromatography is a convenient separation technique 
used for wide types of samples, with exceptional resolving power, speed and nano 
molecular detection levels.   It is presently used in pharmaceutical research and 
developments in the following ways: 
ª To purify synthetic or natural products 
ª To characterize the metabolites. 
ª To assay active ingredients, impurities, degradation products and in dissolution 
assays. 
ª In pharmacodynamic and pharmacokinetic studies. 
          Chromatography encompasses a diverse group of methods that are utilized for 
the separation of closely related components of mixtures.  In all chromatographic 
separations, the sample is transported within the mobile phases, which may be a gas 
(GC), a liquid (LC), or a supercritical fluid (SFC).  In column chromatography, the 
stationary phase is contained within a narrow tube through which the mobile phase is 
forced by gravity or under pressure.  The components of the mixture to be analyzed 
distribute themselves between the mobile phase and stationary phase in varying 
proportions. Compounds that interact strongly with the stationary phase migrate very 
slowly with the mobile phase; in contrast, compounds that are weakly retained by the 
packing material migrate rapidly with the mobile phase.  As a consequence of the 
differences in mobility between the individual components of a mixture, the sample 
components are separated into discrete bands (or zones) that emerge from the column at 
specific ‘retention times’.  These bands may be identified qualitatively and /or further 
analyzed quantitatively using an appropriate detector. 
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          Early, liquid chromatography was carried out in glass columns with diameter of 1 
to 0.5 cm and length of 50 to500 cm. The average diameter of the solid stationary phase 
particles was usually in the 100 to 200 micron range.  Recent technology has allowed 
for the development of packing material with relatively small particles size diameter (3-
10 µ).  This technology resulted in the development of columns with very high 
efficiencies, and consequently has involved the use of more sophisticated 
instrumentation to perform at increased pressures and flows; hence the term High 
Performance Liquid Chromatography (HPLC) was given to this technique. 
          The typical HPLC separation is based on the selective distribution of analytes 
between a liquid mobile phase and an immiscible stationary phase. The sample is first 
introduced by means of an injection port into the mobile phase stream that is delivered 
by a high-pressure pump.  
          The method is popular because it is non-destructive and may be applied to 
thermally liable compounds (unlike GC); it is also a very sensitive technique since it 
incorporates a wide choice of detection methods. With the use of post-column 
derivatisation methods, selectivity and detection limits are improved. HPLC can easily 
be extended to trace determination of compounds that do not usually provide adequate 
detector response. The wide applicability of HPLC as a separation method makes it 
valuable separation tool in many scientific fields. 
 
1.4.1. INSTRUMENTATION   
                               
             The essential parts of the high performance liquid chromatography are the 
solvent reservoir, tubing, pump, injection device, column, detector, and recorder.   
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1.4.1.1. Solvent  reservoir (James, W. Munson, 2001) 
          The composition of the reserviour should render it inert to a variety of aqueous 
and non aqueous mobile phases. Stainless steel and glass are obviously the best 
choices. The volume should be greater than 500ml.   
1.4.1.2. Sample injection system 
          The injection of the sample onto the column creates some unique problem 
because of the high pressure involved in HPLC. While septum injectors can be used in 
HPLC: the loop injector fined the widest use. Direct sample introduction via syringe  in 
HPLC is the simplest form of injection.     
1.4.1.3. Pumps (Willard, 1986) 
1. Syringe pump (screw driven) (or) Displacement pump 
2. Reciprocating pump 
-  Single piston reciprocating pump 
-  Dual head piston reciprocating pump 
-  Reciprocating diaphragm pump 
3. Pneumatic pump (or) Constant pressure pump 
-  Direct pressure pump 
-  Amplifier pump 
1.4.1.4   Mobile Phases (Sethi, 2001) 
In most of the cases, the mobile phases are binary or ternary system. It is 
advisable to filter each solvent before mixing. HPLC grade solvents rarely have 
particulate matter and HPLC system has in-line filters as further guard, but as part of 
preventive maintenance, the chromatographer should resort to filtration of the solvents. 
Even minute particulate matter not visible to the naked eye can pass various problems 
due to accumulation of the same at the head of column such as change in K'  
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value, non-producible flow rate, decrease in selectivity, spurious peaks, increase 
in back pressure, irreversible adsorption and shortening of column life. 
1.4.1.5 Columns (Sethi,  2001; Skoog, 2004) 
           Column is often referred to as the heart of HPLC separation process. Liquid 
chromatographic columns are ordinary constructed from smooth-bore stainless stell 
tubing. Stable high performance column is essential requisite for rugged and 
reproducible method. Columns commercially available differ among the suppliers or 
even the same source in terms of plate number (N), band symmetry, band spacing, 
retention and life time. For high separation efficiency, large number of theoretical 
plates is necessary per unit length of the column. Analytical column and guard columns 
are most common columns for HPLC.  
 
1.4.1.6. Detectors  ( Sethi, 2001; Willard, 1986)  
 
             Detector is the eye of LC system and measures the compounds after the 
separation on the column. Before the first sample is injected, during method 
development the chromatographer must ensure that the detector so selected is capable 
of responding to changes in the concentration of all the components in the sample with 
adequate sensitivity even to measure trace substances. 
 
There are basically two types of detectors. 
- Bulk property detectors  
- Solute property detectors 
The Bulk property detectors function based on some bulk property of the eluent, 
such as refractive index and are not suitable for gradient elution and are usually less 
sensitive than solute property detectors. The solute property detectors perform by 
measuring some type of physical or chemical property.  
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1.4.2.  METHODS IN CHROMATOGRAPHY  (Sethi, 2001 ) 
¾ Adsorption chromatography 
- Normal phase chromatography 
- Reserved phase chromatography 
- Ion exchange chromatography 
- Affinity phase chromatography 
- Hydrophobic Interaction Chromatography (HIC) 
¾ Partition chromatography 
- Gas chromatography 
- Liquid   partition chromatography 
¾ Size Exclusion Chromatography (SEC) 
- Gel permeation chromatography 
- Gel filtration chromatography 
Normal phase chromatography 
Mechanism: Retention by interaction of the stationary phase’s polar surface with polar 
parts of the sample molecules.  
Stationary phase: In the normal phase chromatography, the nature of  stationary phase 
is polar. e.g: SiO2, Al2O3, -NH2,  -CN, -Diol and  -NO2. 
Mobile phase:  Nature of mobile phase is non-polar. e.g: Hectane, hexane, cyclo 
hexane, CHCl3, CH2Cl2, dioxane and methanol. 
Application: Separation of non-ionic, non-polar to medium polar substances. 
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Reverse phase chromatography 
Mechanism:  Retention by interaction of the stationary phase’s non-polar hydrocarbon 
chain with non-polar parts of the sample molecules. 
Stationary Phase:  Nature of stationary phase is non-polar. e.g: n-octadecyl  (C18), n-
octyl (C8), n-hexyl (C6) and ethyl (C2). 
Mobile phase: Nature of mobile phase is polar. e.g:  Methanol or acetronitrile / water or 
buffer (some times with additives of THF or dioxane) 
(Rule of thumb:  Increase of water content by 10% results in doubling the K' value.) 
Application: Separation of non-ionic and ion forming non-polar to medium polar 
substances (carboxylic acids -> hydrocarbons). If ion forming substances (as carboxylic 
acid) are to be separated,  pH control by using buffers is necessary. 
1.4.3. THEORY OF OPERATION 
1.4.3.1. Column efficiency (Llyod, 1997; Willard, 1986) 
           Column efficiency refers to the performance of the stationary phase to 
accomplish particular separations. Column efficiency is a funtion of different 
separation variables. This entails how well the column is packed and its kinetic 
performance. The efficiency of a column can be measured by several methods which 
may or may not be affected by chromatographic anomalies, such as "tailing" or 
appearance of a "front". This is important because many chromatographic peaks do not 
appear in the preferred shape of normal Gaussian distribution. For this reason, 
efficiency can be an enigmatic value since manufacturers may use different methods in 
determining the efficiency of their columns.  
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Calculation of column efficiency value 
           All the following methods use this formula that measures N, or number of 
theoretical plates: 
 a tr2 
              N =         
                        W  
a = constant dependent on height, where peak width is measured 
tr = retention time  
W = peak width  
1.4.3.2. Inflection method 
          Calculation is based upon inflection point which appears at 60.7% of the peak 
height for a normal Gaussian peak. At this point, the width of the peak is equivalent to 
two standard deviation units. Any asymmetrical aspect of a peak should not affect this 
calculation since the width is measured above the anomalous occurrence (i.e., tailing or 
fronting). 
1.4.3.3. Half-peak height method 
          As the name suggests, the measurement is based upon the width at 50% of peak 
height. For the same reason as inflection method, this measurement is not affected by 
asymmetry; however, this method is more reproducible from person to person since 
width at 50% peak height is less prone to be varied. 
1.4.3.4. Tangent method 
          Tangent lines are drawn on each side of the peak and the width is the distance 
between the two lines at the base of the peak. Therefore, it is more sensitive to 
asymmetrical peaks and variation in efficiency values is usually seen from user to user. 
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1.4.3.5. Sigma Method 
 This method measures peak width at decreasing levels of peak height. Thus the 
three sigma method measures width at 32.4% of peak height, the four sigma method 
measures at 13.4%, and the five sigma method measures at 4.4%.The five sigma 
method is most sensitive to asymmetry because the width is measured at the lowest 
point. 
1.4.3.6. Height/Area method 
 This method utilizes the fact that the area of a peak is a function of its height 
and standard deviation. To determine the efficiency, values for peak height and area are 
used in a different formula: 
 2π (htr2) 
N =           
        A2 
                        
Where, 
 N = No. of theoretical plates 
  h = peak height  
 tr = retention time 
  A = peak area 
1.4.3.7. Moment method  
 This method entails disregarding peak shape and expresses parameters of the 
peak in tactical moments. The zero moment, μ0 is the mean and occurs at the center of 
the peak area. The first moment, μ1 is the mean and occurs at the center of the peak 
(which is the maximum peak height in normal Gaussian peaks). The second moment 
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μ2 is the variance of the peak. This is a detailed method, where appropriate data systems 
are needed. For a more detailed discussion, a reference is provided. 
1.4.4. QUANTITATIVE ANALYSIS 
          Quantification involves the measurement of peak height or peak area.   To 
determine the concentration of a compound, the peak area or height is plotted vs the 
concentration of the substance.  For well resolved peaks, both peak height and area are 
proportional to the concentration.   Four different calibration methods used in 
quantitative analysis are, 
a. Normalized peak area 
b. External standard addition method 
c. Internal standard addition method  
d. Standard addition method 
a. Normalized peak area  
After completion of a run and the integration of all significant peaks in the 
chromatogram, the total peak area can be calculated. This technique is widely used to 
estimate the relative amount of small impurities or degradation compound in a purified 
material. The area present of any individual peak is referred to as the normalized peak 
area. The technique of normalized peak area is actually not a calibration method, since 
there is no comparison to a known amount for any peak in the chromatogram.  
b. External standard calibration 
The most general method for determining the concentration of an unknown 
sample is to construct a calibration plot using external standards. Standards are 
prepared at known concentrations. A fixed volume of each standard solution is  
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injected and analyzed, and the peak responses are plotted Vs concentration. The 
standard solutions are referred to as external standards, since they are prepared and 
analyzed in separate chromatograms from those of the unknown samples. Unknown 
samples are then prepared, injected and analyzed in exactly the same manner. 
c. Internal standard calibration 
 Another technique for calibration involves the addition of an internal 
standard to the calibration solutions and samples. The internal standard is a different 
compound form the analyte, but one that is well resolved in the separation. The internal 
standard can compensate for changes in sample size or concentration to instrumental 
variations. With the internal standard method, a calibration plot is produced by 
preparing and analyzing calibration solutions containing different concentration of the 
compound of interest with a fixed concentration of the internal added. 
The Internal standard must complies the following requirements : 
ª Well resolved from the compound of interest and other peaks. 
ª Similar retention (k) to the analyte. 
ª Should not be in the original sample 
ª Should mimic the analyte in any sample preparation steps. 
ª Does not have to be chemically similar to analyte. 
ª Commercially available in high purity. 
ª Stable and unreactive with sample or mobile phase. 
ª Should have similar detector response to the analyte for the concentration used 
ª It must be separated from all compounds of interest in the separation. 
27 
   
d. Method of standard addition 
  A calibration standard ideally should be prepared in a blank matrix of 
drug formulation components without the drug substance or an animal without added 
compound usually can be used for standard calibration solutions. The method of 
standard addition is most often used in trace analysis. In this approach, different 
weights of analyte(s) are added to the sample matrix, which initially contains an 
unknown concentration of the analyte. Extrapolation of a plot of response found for the 
standard addition calibration concentration to zero concentration defines the original 
concentration in the unspiked sample. 
1.5. ICH GUIDELINES FOR ANALYTICAL METHOD VALIDATION 
(Code Q2A, 1996; Code Q2B, 1996)  
          Method validation is the process to confirm that the analytical procedure 
employed for a specific test is suitable for its intended use.  Methods need to be 
validated or revalidated, 
 Before their introduction into routine use 
 Whenever the conditions change for which the method has been validated, e.g., 
instruments with different characteristics. 
 Whenever the method is changed, and the change is outside the original scope 
of the method. The International Conference on Harmonization (ICH) of 
Technical Requirements for the Registration of Pharmaceutical for human use 
has developed a consensus text on the validation of analytical procedures. The 
document includes definitions for eight validation characteristics.  
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The parameters as defined by the ICH and by other organizations 
¾ Specificity 
¾ Selectivity 
ª Precision 
 Repeatability 
 Intermediate precision 
 Reproducibility 
ª Accuracy 
ª Linearity 
ª Range 
ª Limit of detection 
ª Limit of quantization 
ª Robustness 
ª Ruggedness 
 
1.5.1. SPECIFICITY 
 Specificity is the ability to assess unequivocally the analyte in the presence of 
components which may be expected to be present.  Lack of specificity of an individual 
analytical procedure may be compensated by other supporting analytical procedures. 
          An investigation of specificity should be conducted during the validation of 
identification tests, the determination of impurities and the assay.  The procedures used 
to demonstrate specificity will depend on the intended objective of the analytical 
procedure. 
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1.5.2. ACCURACY 
            The accuracy of an analytical procedure expresses the closeness of agreement 
between the value which is accepted either as a conventional true value or on an 
accepted reference value and the value found. 
 1.5.2.1. Assay 
- Assay of Active Substance 
- Assay of Medicinal products    
Several methods are available to determine the accuracy. 
a. Application of an analytical procedure to an analyte of known purity (e.g. 
reference material). 
b. Comparison of the results of the proposed analytical procedure with those of 
a second well-characterized procedure, the accuracy of which is stated 
and/or defined (independent procedure) 
c. Application of the analytical procedure to synthetic mixtures of the product 
components to which known quantities of the substance to be analyzed have 
been added. 
1.5.2.2. Impurity (Quantification) 
          Accuracy should be assessed on sample (substance /products) spiked with known 
amounts of impurities.  It should be clear how the individual or total impurities are to 
be determined. 
 E.g.  Weight / Weight or area percent. 
30 
   
1.5.3. PRECISION 
          The precision of an analytical procedure expresses the closeness of agreement 
between a series of measurement obtained from multiple sampling of the same 
homogenous sample under the prescribed conditions. Precision of an analytical 
procedure is usually expressed at the variance, standard deviation or coefficient of 
variation of a series of measurements. 
          Validation of tests for assay and for quantitative determination of impurities 
includes an investigation of precision. 
1.5.3.1. REPEATABILITY 
          Express the precision under the same operating conditions over a short interval of 
time.  Repeatability is also termed as intra - assay precision. It should be assessed using 
a minimum of nine determinations covering the specified range for the procedure (e.g. 
three concentration/three replicates each) or a minimum of determinations at 100% of 
the test concentration. 
1.5.3.2. INTERMEDIATE PRECISION 
          The extent to which intermediate precision should be established depends on the 
circumstances under which the procedure is intended to be used.  The applicant should 
establish the effects of random events on the precision of the analytical procedure. 
Typical variations to be studied include days, analysts, equipment, etc. 
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1.5.3.3. REPRODUCIBILITY 
          Reproducibility is assessed by means of an inter-laboratory trial.  Reproducibility 
should be considered in case of the standardization of an analytical procedure, for 
instance inclusion of procedures in Pharmacopoeias.   
1.5.4. LINEARITY 
          Linearity of an analytical procedure is its ability (with in a given range) to obtain 
test results which are directly proportional to the concentration (amount) of analyte in 
the sample. 
          Linearity should be evaluated by visual inspection of a plot of signals as a 
function of analyte concentration or content.  If there is a linear relationship, test results 
should be evaluated by appropriate statistical methods.  For example, calculation of a 
regression line by the method of least square.  Therefore data from regression line itself 
may be helpful to provide mathematical estimates of the degree of linearity. 
1.5.5. RANGE 
          Range of an analytical procedure is the interval between the upper and lower 
concentration (amounts) of analyte in the sample including these concentrations for 
which it has been demonstrated that the analytical procedure has a suitable level of 
precision, accuracy and linearity. 
 The following minimum specified ranges should be considered 
- For the assay of an active substance or a finished product normally from 80-
120 percent of the test concentration. 
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- For the content uniformity, covering a minimum of 70-130 percent of the 
test concentration. 
- For dissolution testing, 20% over the specified range (e.g.), If the 
specifications for a controlled release product cover a region from 20% after 
1 hour, upto 90% after 24 hours, the validated range would be 0-110% of 
label claim. 
- For the determination of an impurity, the reporting level of an impurity to 
120% of the specifications. 
1.5.6. LIMIT OF DETECTION  
           The detection limit is determined by the analysis of samples with known 
concentration of analyte and by establishing that minimum level at which the analyte 
can reliably detected. 
i. Based on visual evaluation 
          Visual evaluation may be used for non-instrumental methods but may be used 
with instrumental methods.    
ii. Based on signal to noise ratio 
Determination of the signal-to-noise ratio is performed by comparing measured 
signals from samples with known low concentrations of analyte with those of blank 
samples and establishing the minimum concentration at which the analyte can be 
reliably detected. A signal-to-noise ratio 3 or 2 : l is generally considered acceptable for 
estimating the detection limit. 
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iii. Based on the standard deviation of the response and the slope 
The detection limit (DL) may be expressed as 
 D L = 3.3σ/S 
Where, 
  σ = the standard deviation of the response 
 S = the slope of the calibration curve 
 The slope, S may be estimated from the calibration curve of the analyte. 
The estimate of σ may be carried out in a variety of ways. 
a. Based on the Standard Deviation of the Blank 
          Measurement of the magnitude of analytical background response is performed 
by analyzing an appropriate number of blank samples and calculating the standard 
deviation of these responses. 
b. Based on the calibration curve 
          A specific calibration curve should be studied using samples containing an 
analyte in the range of DL. The residual standard deviation of a regression line or the 
standard deviation of y-intercept of regression lines may be used as the standard 
deviation. 
1.5.7. LIMIT OF QUANTIFICATION  
The quantification limit is generally determined by the analysis of samples with 
known concentrations of analyte and by establishing the minimum level at which the 
analyte can be quantified with acceptable accuracy and precision 
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i. Based on visual evaluation 
            Visual evaluation may be used for non-instrumental methods but may also be 
used with instrumental methods. 
ii. Based on Signal- to-Noise ratio 
Determination of the Signal-to-Noise ratio is performed by comparing measured 
signals from samples with known low concentrations of analyte with those of blank 
samples and by establishing the minimum concentration at which the analyte can be 
reliably quantified. A typical Signal- to-Noise ratio is 10:1. 
iii. Based on the Standard Deviation of the Response and the slope   
 The quantification limit (Q L) may be expressed as 
  
S
10σQL =  
Where, 
 σ = the standard deviation of the response 
 S = the slope of the calibration curve 
 The slope S may be estimated from the calibration curve of the analyte. 
The estimate may be carried out in a variety of ways including, 
a. Based on standard deviation of the blank 
          Measurement of the magnitude of analytical background response is performed 
by an appropriate number of blank samples and calculating the standard deviation of 
these responses. 
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b. Based on the Calibration Curve 
          A specific calibration curve should be studied using samples containing an 
analyte in the range of QL. The residual standard deviation of a regression line or the 
standard deviation of y-intercepts of regression lines may be used as the standard 
deviation. 
1.5.8. ROBUSTNESS 
          The evaluation of robustness should be considered during the development phase 
and depends on the type of procedure under study.  It should show the reliability of an 
analysis with respect to deliberate variations in method parameters. 
Examples of typical variations are 
- Stability of analytical solutions. 
- Extraction time. 
Incase of liquid chromatography, examples of typical are 
- Influence of variation of pH in a mobile phase 
- Influence of variations in mobile phase composition, 
- Different columns (different lots and / or suppliers) 
- Temperature  
- Flow rate 
 
In the case of gas-chromatography, examples of typical variations are 
- Different columns (different lots and/or suppliers), 
- Temperature, 
- Flow rate. 
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1.5.9.   RUGGEDNESS 
          The United States pharmacopoeia (USP) define ruggedness as the degree of 
reproducibility of test results obtained by the analysis of the same samples under a 
variety of normal test conditions such as different labs, different analysis, different lots 
of reagents etc.  Ruggedness is a measure of reproducibility of test results under normal 
expected operational conditions from laboratory to laboratory and from analyst to 
analyst.  
1.6. SYSTEM SUITABILITY PARAMETERS 
        (Anonymous. USP, 1995; Sethi, 2001) 
          System suitability test are an integral part of Gas and Liquid Chromatography.  
They are used to verify that the resolution and reproducibility of the chromatographic 
system a are adequate for the analysis to be done.  These tests are based on the concept 
that the equipment, electronics, analytical operations and samples to be analyzed 
constitute an integral system that can be evaluated as such. 
           There are numerous guidelines which detail the expected limits for typical 
chromatographic methods. In the current FDA guideline on “Validation of 
Chromatographic methods” the following acceptance limits are proposed as initial 
criteria. 
i. Capacity factor (K') 
          It is the measure of a sample peak in the chromatogram being specific for a given 
compound, a parameter which specifies the delay of a substance to be separated. 
            t r - to     
  K' =    
               to 
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Where, 
tr = retention time measured from time of injection to time of elution of peak 
maximum. 
to = void volume 
Limit = generally the value of K' is 1-10. 
ii. Resolution (Rs) 
          The resolution Rs is a function of column efficiency N and is specified to ensure 
that closely eluting compounds are resolved from each other to establish the general 
resolving power of the system and to ensure that internal standards are resolved from 
the drug.            
                     
                                       t2- t1  
Rs =           
                    0.5(w1 - w2) 
 
Where, 
   t1 and t2 = retention times of first and second adjacent bands. 
   Limit = Rs of >2 between the peak of interest and the closest potential  
interfering peak is desirable. 
iii. Tailing factor (T) 
The tailing factor T, a measure of peak symmetry, is unity for perfectly 
symmetrical peaks and its value increases as tailing becomes more pronounced. 
In some cases, values less than unity may be observed. As peak asymmetry 
increases, integration, and hence precision becomes less reliable. 
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         W 0.05  
T =  
              2f 
Where, 
 W0.05 = width of peak at 5% height 
f = Distance from the peak maximum to the leading edge of the peak, the 
distance being measured at a point 5% of the peak height from the baseline. 
Limit: ≤ 2 is preferable.  
iv. Theoretical plates (N) 
           The number of theoretical plates, N is a measure of column efficiency. For 
Gaussian peaks, it is calculated by the equations. 
          N = 16(t / w)2 or 
          N = 5.54(t / w1/2)2   
Where, 
 t = retention time of substance. 
W = width of the peak at its base, obtained by extrapolating the relatively      
straight sides of the peak to the baseline. 
W1/2 = width of the peak at half height, obtained directly by electronic    
   integrators. 
 The value of ‘N’ depends upon the substance being chromatographed as well 
as the operating conditions such as mobile phase, temperature etc. 
Limit = N > 2000 is desirable. 
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1.7. PHARMACEUTICAL STATISTICS  
      (Sanford Bolton, 1990; Kenneth, 2001; Mendham, 1994)   
          Statistical techniques have been widely used in many diverse areas of scientific 
investigation. Statistical applications have been recognized as crucial to quality control 
procedure, test, specification and definitions. Principle of modern analytical techniques 
and skill in their application are necessary attribute of the successful pharmaceutical 
analyst, thus does not ensure the satisfactory solution of all the problem that may 
encountered. Some auxiliary knowledge methods that can aid the analyst in designing 
experiment, collecting data, and interpreting the result. 
1.7.1. Linear regression 
          Linear regression a statistical technique that defines the functional relationship 
between two variable by best-fitting straight line.  Once a linear relationship has been 
shown to have a high probability by the value of the correlation coefficient ‘r’, then the 
best straight line through the data points has to be estimated. This can often be done be 
done by visual inspection of the calibration graph, but in many cases it is far more 
sensible to evaluate the best straight line by linear regression (the method of least 
squares) 
The equation of straight line is  
y =  mx + c 
Where, y the dependent variable is plotted as result of changing x, the independent 
variable. 
         To obtain the regression line ‘y on x’ the slope ‘m’ of the line and the intercept ‘c’ 
on the y axis are given by the following equation. 
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 N Σxy – (Σx) (Σy)  
 m = 
               N Σx2 – (Σx)2 
and 
 (Σy) (Σx2) – (Σx) (Σxy) 
 c =  
                         N Σx2 – (Σx)2 
1.7.2. Correlation coefficient (r) 
         It is a procedure commonly used to characterize quantitatively the relationship 
between variable. Correlation is related to linear regression.  To establish whether there 
is a linear relationship between two variables x1 and y1, use Pearson’s correlation 
coefficient r. 
                   n Σx1y1 - Σx1y1  
         r =  
      {[n Σx12 – (Σx1)2] [n Σy12 – (Σy1)2]}1/2 
 
  Where n is the number of data points. 
  The value of r must lie between +1 and -1, the nearer it is to +1, the greater the 
probability that a definite linear relationship exists between the variables x and y, 
values close to +1 indicate positive correlation and values close to -1 indicate negative 
correlation values of ‘r’ that tend towards zero indicate that x and y are not linearly 
related (they made be related in a non-linear fashion). 
1.7.3. Standard deviation (SD) 
          It is commonly used in statistics as a measure of precision statistics as a 
measure of precision and is more meaningful than is the average deviation. It may  
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be thought of as a root-mean-square deviation of values from their average and is 
expressed mathematically as 
( )
1N
xx
S
ni
1i
i
−
−
=
∑=
=  
Where, 
S is standard deviation. 
If N is large (50 or more) then of course it is immaterial whether the term in the 
denomination is N -1 or N  
Σ       = sum 
x       = Mean or arithmetic average. 
x -x  = deviation of a value from the mean 
N      = Number of observations 
 1.7.4. Percentage relative standard deviation (%RSD) 
          It is also known as coefficient of variation (CV). It is defined as the standard 
deviation (S.D) expressed as the percentage of mean. 
                            C 100
x
S.DRSD  %or  V ×=  
Where,  
S.D is the standard deviation, 
x       = Mean or arithmetic average. 
 The variance is defined as S2 and is more important in statistics than S itself.  
However, the latter is much more commonly used with chemical data. 
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1.7.5. Standard error of mean (SE) 
 Standard error of mean can be defined as the value obtained by division of 
standard deviation by square root of number of observations. It is mathematically 
expressed as  
n
S.D.S.E. =    
Where, 
 S.D = Standard deviation 
n = number of observations. 
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2. REVIEW OF LITERATURE 
 
2.1. CHEMISTRY AND PHARMACOLOGY 
2.1.1. CHEMISTRY OF ALFUZOSIN HC1  
(Susan Budavani, 1998; Anthony Moffat, 1996) 
 
i. STRUCTURE   
 
 
ii. Chemical Name   
(R,S)-N-[3-[(4-amino-6,7-dimethoxy-2-quinazolinyl) methylamino] propyl] tetrahydro-
2-furancarboxamide hydrochloride.  
iii. Molecular Formula 
C19H27N5O4 . HCl  
iv. Molecular weight 
425.9. 
v. Description 
Alfuzosin hydrochloride is a white to off-white crystalline powder  
 
vi. Storage 
Store below 25°C, protected from moisture. 
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vii. Solubility 
It is freely soluble in water, sparingly soluble in alcohol, and practically insoluble in 
dichloromethane. 
 
viii. Melting Point 
 Melting point of Alfuzosin HC1 was identified at 238° C 
 
ix. Identification 
Alfuzosin HC1 was identified and interpreted by IR spectrum which was given in    
Fig-1 
2.1.2. PHARMACOLOGY OF ALFUZOSIN HC1 
(Goodman and Gillman’s, 2001; Parfitt, 1991; www.enwikepedia.com)  
 i. Mechanism of action  
       Alfuzosin HC1 is a quinazoline derivative which acts as a α1-adrenergic blocking 
agent. It is structurally relative to prazosine which exhibits selectivity for α1 adrenergic 
recptors in lower urinary tract. Blockade of these adrenoreceptors can cause relaxation 
of smooth muscle in bladder neck and prostate to relax resulting in an improvement of 
urine flow and a reduction in symptoms of benign prostatic hyperplasia(BPH). 
 
ii. Pharmacokinetics 
a. Absorption 
             The absolute bioavailability of Alfuzosin HC1 10 mg tablets under fed 
conditions is 49%. Following multiple dosing of 10 mg Alfuzosin HC1 under fed 
condition, the time to maximum concentration is 8 hours. 
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b. Distribution 
The volume of distribution following intravenous administration in healthy 
male middle-aged volunteers was 3.2 L/kg. Results of in vitro studies indicate that 
Alfuzosin is moderately bound to human plasma proteins (82% to 90%), with linear 
binding over a wide concentration range (5 to 5,000 ng/ml).  
c. Metabolism 
            Alfuzosin HC1 undergoes extensive metabolism by the liver, with only 11 % of 
the administered dose excreted unchanged in the urine. Alfuzosin is metabolized by 
three metabolic pathways: oxidation, O-demethylation and N-dealkylation. The 
metabolites are not pharmacologically active. CYP3A4 is the principal hepatic enzyme 
isoform involved in its metabolism.  
d. Elimination  
           Following oral administration of Alfuzosin HC1 solution, the recovery of 
radioactivity after 7 days (expressed as a percentage of the administered dose) was 69% 
in feces and 24% in urine. Following oral administration of  Alfuzosin 10 mg tablets, 
the apparent elimination half-life is 10 hours.  
iii. Contra indication 
           Alfuzosin HC1 should not be used in patients with moderate or severe hepatic  
insufficiency, since Alfuzosin blood levels are increased in these patients. Alfuzosin 
should not be co-administered with potent CYP3A4 inhibitors such as ketoconazole, 
itraconazole, and ritonavir, since Alfuzosin blood levels are increased.  Alfuzosin HC1 
is contraindicated in patients known to be hypersensitive to Alfuzosin  HC1. 
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iv. Drug Interactions 
CYP3A4 is the principal hepatic enzyme isoform involved in the metabolism of 
Alfuzosin. Repeated  administration of 400 mg of ketoconazole, a potent inhibitor of 
CYP3A4, increased Alfuzosin Cmax 2.3-fold and AUClast 3.2-fold following a single 10 
mg dose of Alfuzosin. Therefore Alfuzosin should not be co-administered with potent 
inhibitors of CYP3A4 because exposure is increased, (e.g., ketoconazole, itraconazole, 
or ritonavir).  
v. Side effects   
 Body as a whole: pain  
Gastrointestinal system: abdominal pain, dyspepsia, constipation, nausea  
Reproductive system: impotence  
Respiratory system: bronchitis, sinusitis, pharyngitis.  
                                                                                             
vi. Dosage and Administration 
           The recommended dosage is one 10mg  Alfuzosin HCl (extended-release 
tablets) tablet daily to be taken immediately after the same meal each day. The tablets 
should not be chewed or crushed. 
vii. Clinical use    
            Alfuzosin HC1 is indicated for the treatment of the sign and symptoms of 
benign prostatic hyperplasia. Alfuzosin HC1 is not indicated for the treatment of 
hypertension. 
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2.2. REPORTED ANALYTICAL METHODS FOR ALFUZOSIN HC1 
2.2.1. Wiesner J L et al., (2003), Selective, sensitive and rapid liquid 
chromatography tandem mass spectrometry method for the determination of 
Alfuzosin in human plasma. 
          A selective, sensitive and rapid liquid chromatography-tandem mass 
spectrometry method for the determination of alfuzosin in plasma was developed. A PE 
Sciex API 2,000 triple quadrupole mass spectrometer in multiple reaction monitoring 
(MRM) mode, using TurboIonSpray with positive ionization was used. Using prazosin 
as an internal standard, liquid-liquid extraction was followed by C18 reversed-phase 
liquid chromatography and tandem mass spectrometry. The mean recovery for 
alfuzosin was 82.9% with a lower limit of quantification set at 0.298 ng/ml, the 
calibration range being between 0.298 and 38.1 ng/ml. This assay method makes use of 
the increased sensitivity and selectivity of tandem mass spectrometric (MS-MS) 
detection to allow for a more rapid (extraction and chromatography) and selective 
method for the determination of alfuzosin in human plasma. 
 2.2.2. Wei X et al., (2007), On-line solid-phase extraction with a monolithic weak  
cation-exchange column and simultaneous screening of α-adrenergic receptor 
antagonist in human plasma. 
            An on-line SPE-HPLC method, using a monolithic poly(glycidyl methacrylate-    
co-ethylene glycol dimethacrylate ) (poly(GMA-EDMA)) based weak cation-exchange 
(WCX) column, was developed for simultaneous determination of alpha1-adrenergic 
receptor antagonists in human plasma. The monolithic WCX column was prepared by 
an in-situ polymerization protocol and modified stepwise with ethylenediamine and 
chloroacetic acid. On connecting this column to an  
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injection valve, an on-line SPE protocol could be established for removal of matrices 
(mainly proteins and lipids) and preconcentration of four α1-adrenergic receptor 
antagonists in human plasma. This method was validated and then used for 
determination of terazosin, prazosin, doxazosin and Alfuzosin  in clinical plasma 
samples. 
 
2.2.3. Chandra A et al., (2007), Development and Validation of RP-HPLC method 
for the estimation of Alfuzosin HC1 in bulk and Tablets. 
             
              A RP- HPLC method has been developed for the estimation of Alfuzosin HC1 
in Bulk and Pharmaceutical dosage form. The quantification was carried out using a RP 
stainless steel column in isocratic mode, with mobile phase consisting of methanol, 
water, triethyl amine in the ratio of 60 : 39.6 : 0.4 (v/v) and added concentrated formic 
acid to make up to the pH-4 . The mobile phase was pumped at a rate of 0.9 ml/min and 
the detection was carried out at 245 nm and the linearity was found to be in the range of 
10 to 1000 µg/ml. The proposed method was found to be simple, precise, accurate, 
rapid and reproducible for the estimation of Alfuzosin HC1 in bulk and tablets. 
  
 
2.2.4. British Pharmacopoeia-2003, Vol.1, The Department of Health, London.  
      
           BP recommends non-aqueous titration for estimation of Alfuzosin HC1 in bulk 
drug. In this method drug was titrated with 0.1 M perchloric acid and end point is 
determined by potentiometrically. 
 
 
 
 
 
49 
   
2.2.5. Rouchouse A et al., (1990), Direct High-performance liquid 
chromatographic determination of the enantiomers of Alfuzosin in plasma on a 
second generation α 1 -acid glycoprotein chiral stationary phase. 
          A direct liquid chromatographic method was developed for the determination of 
the enantiomers of alfuzosin in human plasma, without derivatization, on a chiral  α 1 -
acid glycoprotein column. The influence of pH, of uncharged organic solvents and of a 
cationic modifier (tetrabutylammonium) of the mobile phase on retention and 
enantioselectivity was evaluated. The enantiomers and an internal standard, structurally 
related to alfuzosin, were extracted from plasma with dichloromethane-diethyl ether 
from alkaline solution, then separated with a mobile phase of 0.025 M phosphate buffer 
(pH 7.4) containing 0.025 M tetrabutylammonium bromide-acetonitrile (94:6, v/v). The 
limit of quantification for each isomer was 1 ng/ml. The method has been applied to the 
determination of the pharmacokinetic profile of Alfuzosin HC1 enantiomers in healthy 
volunteers after intravenous administration of the racemate.  
2.2.6. Giuseppe Carlucci et al., (2006),Determination of Alfuzosin HC1 in human   
Plasma by High-Performance Liquid Chromatography with  Column-Switching. 
          A high - performance liquid chromatographic method for the determination of 
Alfuzosin HC1 in human plasma has been developed and validated. A column-
switching procedure without extraction was used to isolate the drug from biological 
matrix prior to the quantitative analysis. The lower limit of detection for the analyte 
was 1 ng/ml. The method was linear from 2 to 150 ng/ml for human  plasma. Within- 
and between-assay precision and accuracy were all found to be <5.2% at the eight 
concentrations evaluated.   
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2.2.7. Salah Fayed A et al., (2006), Validated HPLC and HPTLC stability-
indicating methods for determination of Alfuzosin HC1 in bulk powder and 
pharmaceutical formulations.  
              Two sensitive, selective, and precise stability-indicating, high-performance 
liquid chromatography and high-performance thin-layer chromatography methods have 
been developed for the determination of Alfuzosin HC1 in the presence of its 
degradation products. Alfuzosin HC1 was subjected to stress alkaline, acidic, oxidative, 
thermal, and photo-degradation. The drug could be well separated from the degradation 
products upon applying the two methods. Separation by HPLC was achieved using an 
Xterra RP18 column and acetonitrile/0.02 M KH2Po4 (pH=3) in a ratio of 20: 80 as 
mobile phase. The flow rate was 1 ml/min. The linearity range was 0.25 to 11 µg/ml 
with mean percentage recovery of 100.26 +/- 1.54.    
     
           The HPTLC method used ALUGRAM Nano-SIL silica gel 60 F254 plates; the 
optimized mobile phase was methanol/ammonia (100:1.2). Quantitatively the spots 
were scanned densitometrically at 245 nm. A second order polynomial equation was 
used for the regression. The range was 0.5-7 microg/spot. The mean percentage 
recovery was 100.13 +/- 1.67.     
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3. AIM AND PLAN OF WORK 
          The drug analysis plays an important role in the development, manufacture and 
therapeutic use of drugs.  Most of the pharmaceutical industries do the quantitative 
chemical analysis to ensure that the raw material used and the final product  thus 
obtained meet certain specification and to determine how much of each components are 
present in the final product.  
          Extensive literature survey reveals that Afuzosin HC1 is a official drug of BP 
2003 which recommends non-aqueous titration for estimation of Alfuzosin Hcl in bulk 
drug only where the end point is determined by potentiometry. The titrimetric method 
has its own limitation is that; it is very difficult to measure small quantity of drug 
sample and less sensitive. Further, literature review revealed, HPLC and HPTLC 
methods have been reported in biological fluids, bulk drug and pharmaceutical dosage 
form, but UV-Spectrophotometric method was not reported. Hence, an attempt is made 
in this project to develop simple, cost effective, sensitive, precise and accurate 
spectrophotometric methods HPLC for Alfuzosin HC1. 
Plan  of  the  developed  experimental  protocol. 
 Selection, Collection and Identification of Alfuzosin HC1 for analysis. 
 Development of simple, cost effective and accurate spectrophotometric 
methods. 
 Development of a rapid and accurate RP-HPLC method using UV detection. 
 Analysis of marketed formulations of Alfuzosin HC1. 
 Validation of proposed methods. 
 Statistical analysis of developed analytical methods.  
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4. MATERIALS AND METHODS 
4.1. MATERIALS 
4.1.1 DRUG SAMPLE AND FORMULATIONS 
 Afuzosin HC1 was generously gifted by Aurobindo Pharma Ltd., Hyderabad.  
The following three formulations containing 10 mg were selected for the study and 
procured from local pharmacy.  
1. Alfoo (F1)        -     Dr. Reddy’s Laboratories, Hyderabad. 
2. Alfusin (F2)        -     Cipla Pharmaceutical Pvt Limited, Mumbai.  
3. Xelflo (F3)          -     Sun Pharma, Mumbai.  
 
4.1.2. REAGENTS AND CHEMICALS  
 All the chemicals used were of analytical and HPLC grade and procured from 
Qualigens India Ltd., Mumbai, Loba Chemicals Ltd., Mumbai and Ranbaxy Fine 
Chemicals Ltd., Mumbai.  The chemicals used for the study are as follows, 
S.No. Chemicals / Solvents used Grade 
1 Sodium Hydroxide Analytical Grade 
2 Chloroform Analytical Grade 
3 Hydrochloric Acid Analytical Grade 
4 Methanol HPLC Grade 
5 Water HPLC Grade & 
Analytical Grade 
6 Ortho phosphoric Acid Analytical Grade 
7 Bromocresol green Analytical Grade 
8 Ethanol Analytical Grade 
9 Potassim dihydrogen ortho phosphosphate Analytical Grade 
10 Potassium Hydrogen phthalate  Analytical Grade 
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4.1.2.1. Preparation of reagents   
a. Acid phthalate buffer solution pH-3.0 (Anonymous. The Indian Pharmacopoeia, 
1996) 
            Place 50 ml of the 0.2 M potassium hydrogen phthalate solution in a 200 ml 
volumetric flask, add 22.3 ml of the 0.2 M HC1 solution and then add water to volume 
and pH was checked with  pH meter. 
b. 0.2 M Potassium Hydrogen Phthalate 
            Dissolved 40.846 gm of potassium hydrogen phthalate in water and dilute with 
water to 1000 ml. 
c. Bromo Cresol Green solution 
            Dissolved 50 mg of the Bromo cresol green in 0.72 ml of 0.1 M sodium 
hydroxide and 20 ml of ethanol (95%). After solution is effected add a sufficient 
quantity of water to produce 100 ml. 
d. 0.1 M Sodium Hydroxide 
              4.2 gm of sodium hydroxide in sufficient CO2 free water to produce 1000 ml.  
e. 1 M HC1 
                85 ml of HC1 was diluted with water to produce 1000 ml.  
f. 0.2 M Hydrochloric acid 
                HC1 was diluted with water to contain 7.292 gm of HC1 in 1000 ml.  
g. 10 mM Phosphate Buffer solution(pH-3) 
       1.360 gm of potassium dihydrogen ortho phosphate was diluted with water 
(HPLC Grade) to 1000 ml. The pH-3 was adjusted with ortho phosphoric acid and 
checked with pH meter 
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4.1.3 INSTRUMENTS   
 
 
Instruments employed for the study were,  
A) SHIMADZU AX-200 Digital balance 
B) SHIMAZU-1700 Double beam UV-VISIBLE  Spectrophotometer with pair of  
      10 mm   matched Quartz cells   
C) HPLC 
- SPD-10Avp SHIMADZU UV-Visible detector 
 - LC- 10ATVP SHIMADZU solvent deliver module  
  D) ELICO SL 159 UV –VIS  Spectrophotometer 
E) ELICO pH METER 
Instruments Specifications  
A) Shimadzu AX – 200 digital balance: (Anonymous.Shimadzu Instruction Manual) 
 
Specifications 
Weighing capacity 200gms 
Minimum display 0.1mg 
Standard deviation ≤ 0.1mg 
Operation temperature range 5 to 40°C 
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B) Shimadzu UV – Visible spectrophotometer: (Anonymous.Shimadzu Instruction 
Manual) 
Model : Shimadzu, UV-1700; Cuvetts: 1cm quartz cells. 
Specifications 
Light source 
20 W halogen lamp, Deuterium lamp. 
Light source position automatic adjustment 
mechanism. 
Monochromator Aberration-correcting concave holographic grating 
Detector Silicon Photodiode 
Stray Light 0.04% or less (220 nm: NaI 10g/l) 
0.04% or less (340 nm: NaNO2 50g/l) 
Measurement wavelength range 190~1100 nm 
Spectral Band Width 1nm or less (190 to 900 nm) 
Wavelength Accuracy ±0.5nm automatic wavelength calibration mechanism 
Recording range Absorbance : -   3.99~3.99Abs 
Transmittance : - 399~399% 
Photometric Accuracy ±0.004Abs (at 1.0 Abs), ±0.002 Abs (at 0.5 Abs) 
Operating  
Temperature/Humidity 
Temperature range : 15 to 35°C 
Humidity range :  35 to 80% (15 to below 30°C) 
   35 to 70% (30 to 35°C) 
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C) Shimadzu High Performance Liquid Chromatography: (Anonymous.Shimadzu 
Instruction Manual) 
Detector Specifications 
Light source Deuterium Arc lamp 
Measurement wavelength range 190 to 700 nm 
Spectral Band Width 5 nm 
Wavelength Accuracy ± 1 nm 
Cell path length 10 nm 
Cell volume  20µl 
Operating temperature range 4 to 35°C (39 to 104°F) 
Recording range 0.0001 to 4.000AUFS 
Operating temperature/Humidity 40 to 75% 
Pump Specifications 
Pump type Double reciprocating plunger pump 
Pumping methods Constant flow delivery and constant pressure 
Suction filter 45 µm 
Line filter 5 µm mesh 
Operating temperature 4 to 35°C (39 to 104°F) 
 
 
D) pH-Meter 
Make   : Elico LI 120 
Electrode   : Deep vision 
pH range   : 0-14 
Electrode temperature range  : 20-100˚C 
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4.2. METHODS 
The analysis of Alfuzosin HC1 was done by following methods: 
            4.2.1. UV-Spectroscopic method 
            4.2.2. Visible Spectrophotometric method 
            4.2.3. High Performance Liquid Chromatographic method  
 
4.2.1. UV SPECTROSCOPIC METHOD  
4.2.1.1 Selection of solvent and λ max 
          The solubility of Alfuzosin HC1 was determined in a variety of solvents as per 
Indian pharmacopeia 1996. Solubility test for Alfuzosin HC1 in non polar and polar 
solvent by increasing dielectric constant was carried out to know solubility and choose 
solvent for the proposed method. From the solubility studies, 0.1M NaOH was selected 
as solvent.  The drug solution was prepared and scanned from 200- 400 nm.  and shows 
constant λ max  at 250 nm and 350 nm. The stability of the absorbance of drug solution 
at these  λ max was checked. It was stable only at  λ max  350 nm, which was taken for the 
proposed method. Alfuzosin HC1 was stable for 180 mins.    
4.2.1.2. Preparation of standard solution 
          An accurately weighed quantity of 25 mg of pure Alfuzosin was dissolved in a 
minimum quantity of 0.1 M NaOH in a 100 ml volumetric flask and the total volume 
was brought to 100 ml with 0.1 M NaOH (250 μg /ml). 
 4.2.1.3. Linearity and calibration 
Into a series of five 25 ml volumetric flask, Aliquots from stock solution        (1, 
1.5, 2, 2.5 & 3ml) were taken and made up to the mark with 0.1M NaOH. The 
absorbance was measured at 350 nm against 0.1 M NaOH as blank. The calibration 
curve was plotted in the concentration range of 10-30 μg/ml. 
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4.2.1.4. Quantification in formulation 
4.2.1.4.1. Preparation of Test solution 
Twenty tablets of each formulation F1, F2 & F3 (Alfoo, Anfusin and Xelflo) 
containing 10 mg of Alfuzosin HCl were accurately weighed and powdered. Powered 
tablet equivalent to 25 mg of Alfuzosin HC1 was transferred into 250 ml volumetric 
flask, added 50 ml of 0.1 M NaOH and sonicated for five minutes and repeated the 
sonication consequently by four time (4×50 ml) to produce 250 ml.  The solution was 
filtered through Whatmann filter paper No.41 (100 μg/ml).  
 
 4.2.1.4.2. Assay procedure 
From above clear solution, transferred 5 ml to a 25 ml standard flask and made 
up to the mark to produce the concentration of 20 μg/ml. The absorbance measurements 
were made six times for each formulation. The amount of Alfuzosin was calculated 
from the respective calibration curve. 
 
4.2.1.5. Recovery studies 
From the pre analyzed formulation, a known quantity of standard solution was 
added and the contents were mixed well, finally made up the volume with 0.1M NaOH. 
Absorbance was measured at its λmax. Amount present was calculated from slope and 
intercept. Then the recovery studies were determined by using the following formula. 
                                            NΣxy - Σx   Σy 
% of Recovery  =                                  x 100 
          NΣx2- (Σx)2 
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Where, 
             N =   Number of observations 
             X =   Amount added in μg/ml 
             Y =   Amount recovered in μg /ml 
 
4.2.1.6. Limit of Detection (LOD) and Limit of Quantification (LOQ) 
Preparation of calibration curve from the serial dilutions of standard was 
repeated for six times. The limit of detection and limit of quantification was calculated 
by using the average value of slope and standard deviation.   
 
4.2.1.7. Repeatability 
Repeatability was done by inter day and intra day precision. The assay 
procedure were repeated three times on the same day and one time each on three 
successive days. 
4.2.2. VISIBLE SPECTROPHOTOMETRIC METHOD 
4.2.2.1. Selection of Colorimetric Studies (Sethi, 2003) 
             Amines in their protonated state form a complex with an anionic species (acidic 
dyes) to form neutral ion-pair complexes which are distinguished by their solubility in 
organic solvents such as chloroform, benzene, dichloromethane etc. Thus by using a 
pairing agent, a colored complex is produced and the amines can thus be measured 
colorimetrically.  The equilibrium expression for ion-pair formulation can be expressed 
as  
                        A+aq + D-aq                               AD 0rg 
60 
   
A+ aq   is protonated amine in aqueous phase, D- aq is the anionic pairing dye in aqueous 
phase and AD org    is the final ion pair complex method has been extensively used in 
this text for estimation of basic nitrogenous substances employing several anionic 
pairing ions (dyes).   
          The compound Alfuzosin HC1 contains tertiary amino group in its side chain 
which was readily complexed with an anionic species (dye) using an ion pairing agent 
in chloroform and the neutral pair complex produced was measured calorimetrically. In 
order to develop a method in visible spectroscopy, its structure-side chain pKa value, pH 
and solubility were studied. Hence the above principle was highly applicable for the 
drug Alfuzosin HC1. 
 
4.2.2.2. Selection of solvent 
           From the solubility table, it was found that the drug of Alfuzosin HC1 was 
soluble in the organic solvent, chloroform. Under acidic conditions, the compound 
Alfuzosin HC1 containing tertiary amino group which readily complexes with bromo 
cresol green (acitic dye) to produce yellow colored complex which was extracted with 
chloroform. The chloroform extract was scanned from 400- 800 nm.  From the spectra, 
λmax was found to be 416 nm. Alfuzosin HC1 was stable for 90 mins in chloroform.  
4.2.2.3. Preparation of Standard Solution 
       About 10 mg of accurately weighed quantity of Alfuzosin HC1 was dissolved in 50 
ml of distilled water and the total volume was brought to 100 ml with water              
(100 µg/ml). 
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4.2.2.4. Optimization of pH       
 The absorbance of Alfuzosin HC1 in different pH of acid phthalate buffer     (pH-
2.4, pH-2.6, pH-2.8, pH-3.0 & pH-3.2) was observed. The pH of the buffer was optimized 
by steady in absorbance. It was found that the absorbance of Alfuzosin in buffer pH-3 
was same up to 90 mins.  
4.2.2.5. Optimization of Dye solution  
           The volume of Bromocresol green was optimized by taking 5 ml of standard 
solution of drug in six separating funnel in which 10 ml of acid phthalate buffer (pH-3) 
and the bromocresol green(dye) 5, 10, 15, 20, 25 and 30 ml were added. Then coloured 
complex was extracted with chloroform. The absorbance of chloroform extract of each 
solution was measured at 416 nm against chloroform as blank. It was found that, 20 ml 
was the optimized volume of dye with the above optimized condition.   
 4.2.2.6. Linearity and calibration  
            From the standard solution 1-5 ml were taken, separately into a separating 
funnel, added 20 ml of dye solution and 2 drops of 1M HC1 to obtained yellow colour 
complex, Then, added 10 ml buffer solution and extracted the yellow colour complex 
with 20, 15 &15 ml of chloroform.  The chloroform layers were combined and diluted 
to 50 ml with chloroform. The absorbance was measured at 416 nm against chloroform 
blank. The calibration curve was plotted in the concentration range of     2-10 μg/ml. 
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4.2.2.7. Quantification in formulations 
i. Preparation of Test solution 
Twenty tablets of each formulations F1, F2 & F3 (Alfoo, Anfusin and Xelflo) 
containing 10 mg of Alfuzosin HC1 were weighed accurately and powered. Powdered 
tablet equivalent to 25 mg of Alfuzosin HC1 was transferred into 250 ml volumetric 
flask, added 50 ml of 0.1M NaOH. It was sonicated for five minutes and repeated the 
sonication with distilled water consequently by four times (4×50 ml) to produce     250 
ml.  The solution was filtered through Whatmann filter paper No.41 (100 μg/ml).  
ii. Assay Procedure 
 From the above clear solution, pipetted out 25 ml to a 50 ml standard flask and 
made upto the mark with distilled water to produce 50 µg/ml. From this, 6 ml of 
solution was transferred to a separating funnel, added 20 ml of dye solution and 2 drops 
of 1M HC1 to obtain yellow color. Then, added 10 ml of acid phthalate buffer solution 
and extracted the yellow colour drug complex with 20, 15 & 15 ml of chloroform. 
Combined the chloroform and obtained the concentration of 6 μg/ml. The above 
procedure was repeated for six times for each formulation. The amount of Alfuzosin 
was calculated from the respective calibration curve. 
4.2.2.8. Recovery 
 To the pre analyzed solution of formulation, a known quantity of standard 
solution was added and the contents were mixed well, finally made up to volume with 
distilled water. Absorbance was measured at its λmax. Amount present was calculated 
from slope and intercept and the recovery studies were calculated.  
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4.2.2.9. Limit of Detection (LOD) and Limit of Quantification (LOQ) 
Preparation of calibration curve from the serial dilutions of standard was 
repeated for six times. The limit of detection and limit of quantification was calculated 
by using the average value of slope and standard deviation.   
4.2.2.10. Repeatability 
Repeatability was done by inter day and intra day precision. The assay 
procedure was repeated three times on the same day and one time each on three 
successive days. 
4.2.3. HIGH PERFORMANCE LIQUID CHROMATOGRAPHIC METHOD 
4.2.3.1. Selection of chromatographic method 
 Proper selection of the method depends upon the nature of the sample, 
molecular weight, and solubility.  The drug selected for the present study was polar.   
So reverse phase chromatography can be used. This RP-HPLC was selected for the 
initial separation because of its simplicity and suitability from the literature and with 
the knowledge of properties, C18 column was chosen as stationary phase with different 
composition of methanol and buffer were used. 
 4.2.3.2. Selection of  λmax   for detection of compound   
          A solution of Alfuzosin HC1 (10 μg/ml) was scanned in UV region using the 
solvent, methanol: buffer (pH-3) in the ratio of 80:20. The λmax was found at 245 nm. 
This wavelength was used for the estimation of Alfuzosin HC1 by HPLC method. 
4.2.3.3. Initial separation conditions 
Following chromatographic conditions were fixed initially to improve the separation of 
drug, 
Stationary phase                 -       C 18 Column (150 mm X 4.5mm i.d., 5 µm) 
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Mobile phase  -       Methanol: Buffer 
Ratio   -       80       :   20 
Detection wavelength     -       245 nm 
Flow rate    -       1 ml/min 
Sensitivity   -       0.01 AUFS 
Operating pressure                  -       160 Kgf/cm2 
Temperature        -       Room temperature 
4.2.3.4. Effect of ratio of mobile phase 
          Under the said conditions, different ratios of mobile phase were attempted using 
methanol: buffer (80:20, 70:30, 60:40 and 50:50). Chromatograms was recorded for all 
the above ratios, system suitability parameters were calculated. 
          It was seen that, while increasing the buffer ratio, optimum parameters results 
were obtained and the peak was sharp, hence the ratio of 50: 50 was selected for further 
studies. 
4.2.3.5. Optimized chromatographic conditions 
 Following optimized chromatographic parameter were used for the 
estimation     of Alfuzosin HC1 
Mode of operation                    -   Isocratic 
Stationary phase                      -    C18 Column (150 mm X 4.5mm i.d., 5 µm) 
Mobile phase   -    Methanol   :  Phosphate Buffer (pH-3) 
Ratio                                        -   50              :      50  
Detection wavelength              -   245nm 
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Flow rate                                 - 1.0 ml/min 
Temperature                             - Ambient 
Sample volume                         -   20 μl 
4.2.3.6. Preparation of standard Alfuzosin HC1 solution 
           An accurately weighed quantity of 50 mg of alfuzosin HC1 was dissolved in a 
minimum quantity of mobile phase in 50 ml volumetric flask. The total volume was 
brought to 50 ml with more mobile phase (1000 μg/ml).   
4.2.3.7. Linearity and calibration   
         From the standard solution 1 ml was transferred into a 50 ml standard flask and 
made up to the mark with mobile phase to produce 20 µg /ml. To the series of  five 10 
ml standard flask, added 0.5 to 2.5 ml of above solution and made up to  the mark to 
obtain the concentration range from 1 to 5 µg/ml and the calibration curve was plotted 
between concentration and peak area. 
4.2.3.8. Quantification in formulations 
i. Preparation of Alfuzosin HC1 test solution 
          Twenty tablets of F1 formulation (Alfoo) containing 10 mg of Alfuzosin HC1   
was weighed accurately and powered. Powdered tablet equivalent to 20 mg of 
Alfuzosin HC1 was transferred into 100 ml volumetric flask. To this, 50 ml of 
methanol was added and sonicated for 15 minutes. Then it was made up to the volume 
with methanol (20 µg/ml). The solution was filtered through membrane filter           
(0.45 µm).  
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ii. Assay procedure 
          From the above clear solution, pipetted out 5 ml to a 50 ml standard flask and 
made up to the mark with mobile phase to produce 20 µg/ml. The 1.5ml of above 
solution was transferred into a 10 ml volumetric flask to produce 3 µg/ml solutions. 
The peak area measurements were done by injecting the sample (3 µg/ml) six times and 
the amount of Alfuzosin calculated from the respective calibration curve. 
4.2.3.9. Recovery experiments 
           To ensure the reliability of the method, recovery studies were carried out by 
mixing a known quantity of standard drug with the pre analyzed by the proposed 
method. The percentage of recovery was calculated. 
4.2.3.10. System Suitability Studies 
          The system suitability studies were carried out as specified in ICH guidelines and 
USP. The parameters like, Tailing factor, Asymmetric factor, Theoretical plate and 
Capacity factor were calculated. 
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5. RESULTS AND DISCUSSION 
UV-VISIBLE SPECTROSCOPIC METHODS 
            To ensure the percentage purity of Alfuzosin HC1 in various formulations, the 
UV-Visible spectroscopic methods were developed. The methods were very simple, 
economic and applicable for quantification of drug in bulk and in formulations. 
5.1. UV-Spectroscopic method 
          The solubility of Alfuzosin HC1 was determined in a variety of solvents as per IP 
1996. The solvents ranging from non-polar to polar were used. The solvents used were 
water, 0.1M HC1, 0.1M NaOH, methanol, acetonitrile, acetone, chloroform, diethyl 
ether, dichloroethan, ethyl acetate, dimethyl formamide and ethanol.  To the drug (10 
mg) in the test tube, added solvent slowly, initially solubility was checked in water, 
later proceed to other solvents.  The solubility profile of Alfuzosin HC1 was given in   
Table- 1 
          From solubility studies, water and 0.1M sodium hydroxide was chosen as a 
solvent for the proposed method. But due to the instability of Alfuzosin HC1 in water, 
only 0.1 M NaOH was used for UV-spectroscopic studies of the drug in bulk and its 
formulation. 
          Drug was dissolved in 0.1M NaOH and made further dilutions with 0.1M NaOH 
to produce 15 μg/ml. It was scanned in the range of 200 - 400 nm and shows constant 
λmax at 250 nm and 350 nm. This is shown in Fig.2. The stability of the absorbance of 
drug solution at these λmax was checked. It was stable only at  λmax   350 nm, which was 
taken for the proposed method. 
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          The linearity of the Alfuzosin HC1 was found from its calibration curve which 
was shown in Fig-3. The optical characteristic such as beers law limits (10 - 30 μg/ml), 
molar extinction co-efficient (5545.056), sandell’s sensitivity (0.07485), correlation 
coefficient (0.999914), slope (0.01336) and intercept (0.0088) were calculated and were 
shown in Table- 3.   
          The limit of detection and the limit of quantification were determined from the 
linearity studies which have been done six times and then LOD and LOQ was 
calculated by using slope and standard deviation. The limit of detection was found to be 
2.57 µg/ml and the limit of quantification was found to be 7.79 µg/ml. They have been 
shown in Table -3. 
          From the linearity curve, the middle concentration of 20 μg/ml was selected and 
quantification of drug in formulation was performed. The formulations of Alfoo, 
Alfusin and Xelflo were selected for analysis. The amount present was determined by 
average of six replicate analyses and it was found to be 9.81 mg, 9.96 mg and      10.00 
mg respectively. The results were shown in Table -3 to 5. 
           To evaluate the accuracy of the proposed method, a known amount of pure drugs 
were added to the previously analyzed solution containing pharmaceutical formulations 
and their recoveries were calculated. The percentage recovery of Alfoo, Alfusin and 
Xelflo was 100.05%, 100.81% and 99.49% respectively. These values were given in 
Table- 6 to 8. 
          Precision of the proposed method has been done by inter day and intraday 
analysis of formulation.  The assay procedure was repeated three times on the same day 
and one time each three successive days. The percentage standard deviation for 
interday and intraday analysis of formulations was found and given in the Table-9-11. 
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5.2. Visible spectroscopic method 
              The drug was dissolved in distilled water and diluted to prepare require 
concentration of 25 µg/ml. The compound Alfuzosin HC1 containing tertiary amino 
group which readily complexed with bromocresol green dye and produced yellow 
colour complex under acetic condition. The coloured drug complex was extracted with 
chloroform and produced a concentration of 2.5 µg/ml. It was scanned in the range of 
250 - 600 nm and it shows the constant λmax at 416 nm.  This is shown in    Fig-4. 
Stability of absorption at their λmax was also checked. 
             The linearity of the Alfuzosin HC1 was found from its calibration curve which 
was shown in Fig-5.  The optical characteristics such as beers law limits (2–10 μg/ml), 
molar extinction co-efficient (23319.18), sandell’s sensitivity (0.016706348), 
correlation coefficient(0.99958), slope(0.05986) and intercept (0.0002063) were 
calculated and shown in Table- 12. The results were found to be satisfactory.   
 The limit of detection and the limit of quantification were determined from the 
linearity studies which have been done six times and then LOD and LOQ was 
calculated by using slope and standard deviation. The limit of detection was found to be 
0.180706281µg/ml and the limit of quantification was found to be 0.547594 µg/ml. 
They have been shown in Table – 12. 
             From the linearity curve, the middle concentration of 6 μg/ml was selected and 
quantification of Alfuzosin HC1 in formulations were performed. The formulations of 
Alfoo, Alfusin and Xelflo were selected for analysis and the amount present was found 
to be 9.92 mg, 10.00 mg and 9.84 mg respectively. The results were shown in Table - 
13 to15. 
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            To evaluate the accuracy of the proposed method, a known amount of pure 
drugs were added to the previously analyzed solution containing pharmaceutical 
formulation and the recoveries were calculated.  The percentage recovery of Alfoo, 
Alfusin and Xelflo was 99.16 %, 99.82% and 99.50% respectively. The values were 
given in Table -16 to18. 
  Precision of the proposed method has been done by inter day and intraday 
analysis of formulation.  The assay procedure was repeated three times on the same day 
and one time each three successive days. The percentage standard deviation for 
interday and intraday analysis of formulations was found and given in the            Table 
– 19 to 21 
5.3. RP - HPLC METHOD 
              An effort has been made to identify a simple, cost effective, economic, specific 
and accurate method for the estimation of Alfuzosin HC1 in raw material and 
formulations. 
             The λmax of Alfuzosin HC1 in mobile phase was found at 245 nm. The four 
different combinations of mobile phase were employed for the optimization of HPLC 
analysis.  A mobile phase consisting of methanol : 10 mM phosphate buffer-( pH 3) in 
ratio of 80 : 20, 70 : 30, 60 : 40 and 50 : 50 was used and chromatogram were recorded 
at the flow rate of 1.0 ml/min, which were shown in Fig- 6 to 9  respectively. 
          Numbers of peaks were produced and the system suitability parameters were not 
with in the limits in the ratio of 80 : 20, 70 : 30 and 60 : 40 of mobile phase. So these 
three ratio of mobile phases were not selected for HPLC studies. But the parameters 
were within the limit in 50: 50 ratio of mobile phase. 
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          Concentrations of raw material such as 1-5 μg/ml of Alfuzosin HC1 were 
injected and the chromatograms were recorded.  They were shown in the Fig. 10-14 and 
the calibration curve for the same concentrations was plotted against peak area and 
shown in Fig. 15.  The optical characteristics such as beers law limits (1-5μg/ml), molar 
extinction co-efficient (6.22363E+11), sandell’s sensitivity (6.82194E - 10), correlation 
coefficient (0.9995), slope (1465781.9) and intercept (– 45649.76) were calculated and 
shown in Table-23.   The results were found to be satisfactory.   
          The system suitability test parameters such as Theoretical plates   (3090), Tailing 
factor (1.45), Asymmetric factor (1.71) and Capacity factor (0.96) were calculated for a 
mean concentration of 3 μg/ml and were shown in the Table- 22.  The parameters were 
found to be satisfactory as per USP guidelines. Injection repeatability was performed 
for same concentrations six times to the formulation (Alfoo) and the amount present 
was found to be 9.91 mg. The values were shown in Table-24.  Hence, precision was 
confirmed by repeatable injection of the formulation and chromatograms were shown 
in the Fig-16 to 21. 
         Accuracy was confirmed by recovery studies by adding known amount of pure 
drug to the previously analyzed formulation and the mixture was analyzed by the 
proposed method and chromatograms were shown in the Fig-22 to 27. The percentage 
recovery of Alfoo was found to be 99.86 %.  The values were given in the Table-25. 
The results indicated that the excipients and additives did not interfer in the developed 
method. 
         All the above parameters combined with the simplicity and ease of operation 
ensures that the proposed method may be applied for the estimation of Alfuzosin HC1 
in raw material and pharmaceutical dosage forms. 
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6. SUMMARY AND CONCLUSION 
           The proposed analytical methods are simple, economical, rapid, sensitive, 
reproducible and accurate for the estimation of Alfuzosin HC1.  The method adopted 
for our studies are, 
1. UV spectroscopic method  
2.  Visible spectroscopic method and  
3.   RP-HPLC method. 
¾ The drug samples were analyzed by UV spectroscopy method  using  0.1M 
NaOH  as solvent  at λmax 350 nm and the content of drug present in each 
formulation was found to be, 
• Alfoo      -     9.81 mg     (98.10%) 
• Alfusin    -    9.96  mg    (99.60%) 
• Xelflo      -  10.00  mg (100.00%) 
¾ The drug samples were also analysed by visible spectroscopy by using Ion-pair 
complex method. The λmax was found at 416 nm. The content of drug present in 
each formulation was found to be, 
• Alfoo          -  9.92  mg   (99.20%) 
• Alfusin        -             10.00  mg (100.00%) 
• Xelflo         -   9.84  mg   (98.40%) 
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¾ Simultaneously, a newer RP-HPLC method was developed for both bulk drug 
and formulations.  The proposed method gives reliable assay results with short 
analysis time (3.0 mins) using the mobile phase methanol:  phosphate buffer- 
(pH 3) at λmax 245 nm. The content of drug present in the formulation, Alfoo was 
found to be 9.92 mg (99.20 %).  
             All the above methods do not suffer from any interference due to common 
excipients.  Therefore it was found that the proposed methods could be successfully 
applied to estimate commercial pharmaceutical products containing Alfuzosin HC1.  
Thus, the above studies and findings will enable the quantification of the drug for 
future investigation in the field of analytical chemistry. 
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FIG -1 
IR SPECTRUM OF ALFUZOSIN HC1 
 
 
 
 
 
 
 
   
 
 
FIG -2 
UV- SPECTRUM OF ALFUZOSIN HC1 USING 0.1M NaOH 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
FIG -3 
CALIBRATION CURVE FOR UV METHOD USING 0.1M NaOH 
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FIG -4 
 
VISIBLE ABSORPTION SPECTRUM OF ALFUZOSIN HC1 USING  
CHLOROFORM 
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FIG -5 
CALIBRATION CURVE OF VISIBLE METHOD OF ALFUZOSIN HC1 USING 
CHLOROFORM 
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FIG -6 
OPTIMIZATION OF CHROMATOGRAM BY CHANGING MOBILE PHASE 
COMPOSITION METHANOL: BUFFER (pH-3) 
(80:20) 
 
 
 
 
 
 
 
 
 
 
 
   
FIG -7 
OPTIMIZATION OF CHROMATOGRAM BY CHANGING MOBILE PHASE 
COMPOSITION METHANOL: BUFFER (pH-3)    
   (70:30) 
   
 FIG -8 
OPTIMIZATION OF CHROMATOGRAM BY CHANGING MOBILE PHASE 
COMPOSITION METHANOL: BUFFER (pH-3) 
(60:40) 
 
 
 
 
 
 
 
 
 
   
FIG -9 
OPTIMIZED CHROMATOGRAM IN MOBILE PHASE METHANOL: BUFFER (pH-3) 
(50:50) 
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FIG -10 
HPLC CHROMATOGRAM OF ALFUZOSIN HC1 IN MOBILE PHASE  
(1 μg/ml) 
   
 
 
 
 
   
FIG -11 
HPLC CHROMATOGRAM OF ALFUZOSIN HC1 IN MOBILE PHASE  
(2 μg/ml) 
 
 
   
FIG -12 
HPLC CHROMATOGRAM OF ALFUZOSIN HC1 IN MOBILE PHASE 
 (3 μg/ml) 
 
   
FIG -13 
HPLC CHROMATOGRAM OF ALFUZOSIN HC1 IN MOBILE PHASE  
(4 μg/ml) 
 
 
   
FIG -14 
HPLC CHROMATOGRAM OF ALFUZOSIN HC1 IN MOBILE PHASE  
(5 μg/ml) 
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FIG -15 
 
CALIBRATION CURVE FOR RP-HPLC METHOD USING MOBILE PHASE 
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 FIG -16 
HPLC CHROMATOGRAM OF FORMULATION FOR REPEATABILITY I  
ALFOO  (3 μg/ml) 
 
 
   
FIG -17 
HPLC CHROMATOGRAM OF FORMULATION FOR REPEATABILITY II 
ALFOO (3 μg/ml) 
  
 
 
   
FIG -18 
HPLC CHROMATOGRAM OF FORMULATION FOR REPEATABILITY III 
ALFOO (3 μg/ml) 
  
   
       FIG -19 
HPLC CHROMATOGRAM OF FORMULATION FOR REPEATIBALITY IV  
ALFOO (3 μg/ml) 
  
 
 
 
 
   
FIG -20 
HPLC CHROMATOGRAM OF FORMULATION FOR REPEATIBALITY V  
ALFOO (3 μg/ml) 
  
   
FIG -21 
HPLC CHROMATOGRAM OF FORMULATION FOR REPEATABILITY VI 
 ALFOO (3 μg/ml) 
 
   
FIG -22 
HPLC CHROMATOGRAM FOR THE RECOVERY OF FORMULATION (ALFOO)  
 (2 μg/ml) 
  
 
 
 
 
 
 
   
FIG -23 
HPLC CHROMATOGRAM FOR THE RECOVERY OF FORMULATION (ALFOO)          
(2. 5 μg/ml) 
  
 
 
 
 
   
FIG -24 
HPLC CHROMATOGRAM FOR THE RECOVERY OF FORMULATION (ALFOO)      
(3 μg/ml) 
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FIG -25 
HPLC CHROMATOGRAM FOR THE RECOVERY OF FORMULATION (ALFOO)       
(3.5 μg/ml) 
   
 
 
 
   
FIG -26 
HPLC CHROMATOGRAM FOR THE RECOVERY OF FORMULATION (ALFOO)       
(4 μg/ml) 
  
   
                                                                  FIG-27 
HPLC CHROMATOGRAM FOR THE RECOVERY OF FORMULATION (ALFOO)       
(4.5 μg/ml) 
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TABLE – 1 
RESULTS OF SOLUBILITY OF ALFUZOSIN HC1 IN POLAR AND 
NONPOLAR SOLVENTS 
 
 
S.No. SOLVENTS STATUS  
1. Water  Very soluble 
2. 0.1N HCl Very soluble 
3. 0.1N NaOH Very soluble 
4.  Methanol Very soluble 
5.  Ethanol Freely soluble 
6.  Acetonitrile Freely soluble 
7.  Dimethyl formamide Freely soluble 
    8.  Acetone Very soluble 
9.  Chloroform Soluble 
10. Ethyl acetate Insoluble    
11. Dichloroethane Insoluble    
12 Diethyl ether Insoluble 
 
 
 
 
 
   
 
TABLE - 2 
OPTICAL CHARACTERISTICS OF ALFUZOSIN HC1 BY  
UV METHOD 
Parameters Values  
λmax(nm) 350 
Beers law limit (μg/ml) 10-30 
Sandell’s sensitivity (μg/cm2/0.001 A.U) 0.074850299 
Molar absorptivity (L mol–1 cm–1) 5545.056 
Correlation coefficient (r) 0.999914 
Regression equation (y = mx + c) Y = 0.01336 X + 0.0088 
Slope(m) 0.01336 
Intercept(c) 0.0088 
LOD (μg/ml) 2.57 
LOQ (μg/ml) 7.793 
Standard error of mean of Regression line 0.001591645 
 
 
 
 
 
 
 
 
 
   
 
TABLE – 3 
QUANTIFICATION OF FORMULATION –ALFOO 
BY UV METHOD 
 
 
S.No 
Labeled 
amount 
(mg/tab) 
Amount 
found(mg)
Percentage 
obtained 
Average S.D. %RSD S.E. 
9.80 98.00     
9.83 98.30     
9.80 98.00 98.10 0.1629 0.1660 0.004
9.80 98.00     
9.80 98.00     
1. 
2. 
3. 
4. 
5. 
6. 
10.00 
10.00 
10.00 
10.00 
10.00 
10.00 9.83 98.30     
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
TABLE – 4 
QUANTIFICATION OF FORMULATION –ALFUSIN 
BY UV METHOD 
 
 
S.No 
Labeled 
amount 
(mg/tab) 
Amount 
found(mg)
Percentage 
obtained 
Average S.D. %RSD S.E. 
10.00  9.80 98.00     
10.00 10.00 100.00     
10.00 10.10 101.00 99.68 1.315 1.31 0.036
10.00  9.80  98.00     
10.00  9.96  99.60     
1. 
2. 
3. 
4. 
5. 
6. 10.00     10.15 101.50     
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
   
TABLE - 5 
QUANTIFICATION OF FORMULATION –XELFLO 
BY UV METHOD 
 
 
S.No 
Labeled 
amount 
(mg/tab) 
Amount 
found(mg)
Percentage 
obtained 
Average S.D. %RSD S.E. 
10.00 10.06 100.60     
10.00  9.91    99.10     
10.00  9.91   99.10 100.00 1.188 1.187 0.033
10.00  9.91  99.10     
10.00 10.13 101.30     
1. 
2. 
3. 
4. 
5. 
6. 
10.00 10.10 101.00     
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
TABLE – 6 
RECOVERY STUDIES FOR FORMULATION - ALFOO  
BY UV METHOD 
 
 
S.No 
Amount 
Present 
(µg/ml) 
Amount 
Added 
(µg/ml) 
Amount 
Estimated 
(µg/ml) 
Amount 
Recovered 
(µg/ml) 
% 
Recovery 
S.D. %RSD S.E. 
9.95 5 14.76 4.84 102.00    
9.90 6 15.46 5.58 99.50    
9.84 7 16.90 7.12 100.80 1.668 1.663 0.046
9.84 8 17.73 7.89   99.01    
9.83 9 18.54 8.75 100.24    
1. 
2. 
3. 
4. 
5. 
6. 
9.80 10 19.62 9.82  98.80    
    Mean 100.05   
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
TABLE – 7 
RECOVERY STUDIES FOR FORMULATION – ALFUSIN 
BY UV METHOD  
 
S.No 
Amount 
Present 
(µg/ml) 
Amount 
Added 
(µg/ml) 
Amount 
Estimated
(µg/ml) 
Amount 
Recovered
(µg/ml) 
% 
Recovery
S.D. %RSD S.E. 
9.94 5 14.65 4.72  99.50    
9.94 6 16.03 6.01 100.60    
9.94 7 16.52 6.63 101.70 0.957 0.951 0.0026
9.98 8 17.77 7.75 100.60    
9.94 9 18.58 8.62 102.08    
1. 
2. 
3. 
4. 
5. 
6. 10.02 10 19.98 9.96 100.43    
    Mean 100.81   
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
TABLE – 8 
RECOVERY STUDIES FOR FORMULATION – XELFLO 
BY UV METHOD  
 
S.No 
Amount 
Present 
(µg/ml) 
Amount 
Added 
(µg/ml) 
Amount 
Estimated
(µg/ml) 
Amount 
Recovered
(µg/ml) 
% 
Recovery
S.D. %RSD S.E. 
9.82 5 14.65 4.87  98.10    
9.80 6 15.47 5.68 101.10    
9.85 7 16.36 6.62 98.00 1.454 1.462 0.0404
9.81 8 17.49 7.68 100.80    
9.83 9 18.51 8.70  98.44    
1. 
2. 
3. 
4. 
5. 
6. 9.83 10 19.61 9.78 100.50    
    Mean 99.49   
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
TABLE – 9 
INTER DAY AND INTRADAY ANALYSIS OF FORMULATION   
ALFOO BY UV METHOD 
 
 
S.No INTERDAY 
( Amount found in mg) 
INTRA DAY 
( Amount found in mg) 
 
1. 
2. 
3. 
4. 
5. 
6. 
 
9.80 
9.80 
9.85 
9.85 
9.83 
9.88 
 
9.83 
9.85 
9.86 
9.80 
9.80 
9.93 
S.D 0.03355 0.0485 
%RSD 0.3410 0.4925 
 
 
 
 
 
 
 
 
 
 
 
 
   
TABLE – 10 
INTERDAY AND INTRADAY ANALYSIS OF FORMULATION – ALFUSIN 
BY UV METHOD 
 
S.No INTERDAY 
( Amount found in mg) 
INTRA DAY 
( Amount found in mg) 
 
1. 
2. 
3. 
4. 
5. 
6. 
 
9.80 
9.81 
9.80 
9.84 
9.80 
9.80 
 
9.81 
9.80 
9.80 
9.87 
9.80 
9.88 
S.D 0.0178 0.0392 
%RSD 0.1824 0.3991 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
TABLE – 11 
INTER DAY AND INTRA DAY ANALYSIS OF FORMULATION – XELFLO 
BY UV METHOD 
 
S.No INTERDAY 
( Amount found in mg) 
INTRA DAY 
( Amount found in mg) 
 
1. 
2. 
3. 
4. 
5. 
6. 
 
9.81 
9.82 
9.81 
9.83 
9.87 
9.80 
 
9.86 
9.80 
9.82 
9.83 
9.80 
9.84 
S.D 0.0250 0.0240 
%RSD 0.2548 0.2448 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
TABLE - 12 
OPTICAL CHARACTERISTICS OF ALFUZOSIN HC1 BY  
COLORIMETRIC METHOD 
 
Parameters Values  
λmax(nm) 416 
Beers law limit (μg/ml) 2-10 
Sandell’s sensitivity (μg/cm2/0.001 A.U) 0.016706348 
Molar absorptivity (L mol–1 cm–1) 23319.1881 
Correlation coefficient (r) 0.999588 
Regression equation (y = mx+c) Y=0.059864286X + 0.000206349 
Slope(m)  0.059864286 
Intercept(c)  0.000206349 
LOD (μg/ml) 0.180706281 
LOQ (μg/ml) 0.547594 
Standard error of mean of Regression line 0.000518438 
 
 
 
 
 
 
 
 
   
TABLE – 13 
QUANTIFICATION OF FORMULATION –ALFOO 
        BY COLORIMETRIC METHOD 
 
 
S.No 
Labeled 
amount 
(mg/tab) 
Amount 
found(mg)
Percentage 
obtained 
Average S.D. %RSD S.E. 
9.86  98.60     
10.01 100.10     
9.98  99.80 99.28 1.5819 1.5814 0.0439
10.02 100.20     
9.90  99.00     
1. 
2. 
3. 
4. 
5. 
6. 
10.00 
10.00 
10.00 
10.00 
10.00 
10.00 9.80  98.00     
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
TABLE – 14 
QUANTIFICATION OF FORMULATION –ALFUSIN 
          BY COLORIMETRIC METHOD 
 
 
S.No 
Labeled 
amount 
(mg/tab) 
Amount 
found(mg)
Percentage 
obtained 
Average S.D. %RSD S.E. 
   9.95    99.50     
 10.10  101.00     
  9.98   99.80 100.00 0.9230 0.9230 0.0256
 10.10 101.00     
 10.01 100.10     
1. 
2. 
3. 
4. 
5. 
6. 
10.00 
10.00 
10.00 
10.00 
10.00 
10.00   9.86     98.60     
 . 
 
 
 
 
 
 
 
 
 
 
 
   
TABLE – 15 
QUANTIFICATION OF FORMULATION –XELFLO 
       BY COLORIMETRIC METHOD 
 
 
S.No 
Labeled 
amount 
(mg/tab) 
Amount 
found(mg)
Percentage 
obtained 
Average S.D. %RSD S.E. 
 9.82  98.20      
 9.80  98.00     
  9.80   98.00 98.40  0.9042  0.9178   0.0251 
 9.80   98.00     
  9.80   98.00     
1. 
2. 
3. 
4. 
5. 
6. 
10.00 
10.00 
10.00 
10.00 
10.00 
10.00 
 10.03 100.30     
 
  
 
 
 
 
 
 
 
 
 
 
   
TABLE – 16 
RECOVERY STUDIES FOR FORMULATION ALFOO  
BY COLORIMETRIC METHOD 
  
S.No 
Amount 
Present 
(µg/ml) 
Amount 
Added 
(µg/ml) 
Amount 
Estimated
(µg/ml) 
Amount 
Recovered
(µg/ml) 
% 
Recovery
S.D. %RSD S.E. 
 2.95 1  3.819   0.871    98.00     
 2.95  2  4.729  1.778  100.20    
 2.95  3  5.882  2.932    98.80 1.7713  1.7835 0.0492 
 2.95  4  6.793  3.844    98.80    
 2.95  5  7.853  4.916    98.40    
1. 
2. 
3. 
4. 
5. 
6.  2.95  6  8.699  5.759  100.80    
    Mean 99.16   
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
TABLE – 17 
RECOVERY STUDIES FOR FORMULATION – ALFUSIN 
BY COLORIMETRIC METHOD 
 
 
S.No 
Amount 
Present 
(µg/ml) 
Amount 
Added 
(µg/ml) 
Amount 
Estimated
(µg/ml) 
Amount 
Recovered
(µg/ml) 
% 
Recovery
S.D. %RSD S.E. 
2.90  1   3.885   0.935    98.30     
 2.90  2  4.710     1.768  102.50    
 2.90  3  5.834  2.8845   99.66 1.6933 1.6967 0.0470
 2.90  4  6.806  3.85635   98.03    
 2.90  5  7.875  4.924   99.37    
1. 
2. 
3. 
4. 
5. 
6.  2.90  6  8.785  5.836  101.09    
    Mean 99.82    
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
TABLE -18 
RECOVERY STUDIES FOR FORMULATION – XELFLO 
BY COLORIMETRIC METHOD 
 
 
S.No 
Amount 
Present 
(µg/ml) 
Amount 
Added 
(µg/ml) 
Amount 
Estimated
(µg/ml) 
Amount 
Recovered
(µg/ml) 
% 
Recovery
S.D. %RSD S.E. 
2.95 1   3.813    0.862    102.00     
 2.95  2  4.492   1.542  98.00    
 2.95  3  5.661  2.726  98.00 1.90 1.917  0.0528  
 2.95  4  6.500  3.522  100.00    
 2.95  5  7.815  4.865  99.80    
1. 
2. 
3. 
4. 
5. 
6.  2.95  6  8.591   5.663  99.20    
    Mean   99.50   
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
TABLE – 19 
INTERDAY AND INTRADAY ANALYSIS OF FORMULATION – ALFOO 
BY COLORIMETRIC   METHOD 
  
S.No 
                INTERDAY    
     ( Amount found in mg) 
INTRA DAY 
( Amount found in mg) 
 
1. 
2. 
3. 
4. 
5. 
6. 
 
 10.01 
10.08  
 9.89 
 9.99 
 9.89 
 9.94 
              
9.94 
10.06  
 10.03 
 10.03 
 9.96 
 9.90 
  
S.D 0.0909 0.0625 
%RSD 0.9136 0.6258 
 
 
 
 
 
 
 
 
 
 
 
 
   
TABLE – 20 
INTERDAY AND INTRADAY ANALYSIS OF FORMULATION –ALFUSIN 
BY   COLORIMETRIC METHOD 
 
S.No INTERDAY 
( Amount found in mg) 
INTRA DAY 
( Amount found in mg) 
 
1. 
2. 
3. 
4. 
5. 
6. 
 
9.94 
9.96 
9.86 
9.90 
10.50 
10.03 
 
10.06 
 
10.00 
 
10.07 
 
10.06 
 
10.13 
 
10.13 
 
 
 
S.D 0.1075 0.0492 
%RSD 1.078 0.4892 
  
 
 
 
 
 
 
   
TABLE – 21 
INTERDAY AND INTRADAY ANALYSIS OF FORMULATION – XELFLO 
BY   COLORIMETRIC METHOD 
 
S.No INTERDAY 
( Amount found in mg) 
INTRA DAY 
( Amount found in mg) 
 
1. 
2. 
3. 
4. 
5. 
6. 
 
 
 
 
 
 
9.92 
9.98 
9.86 
10.20 
10.00 
10.06 
 
10.13 
 
10.10 
 
10.10 
 
10.09 
 
10.20 
 
10.07 
 
 
S.D 0.1182 0.0480 
%RSD 1.1822 0.4748 
  
 . 
 
 
 
 
 
 
 
 
    
   
   TABLE – 22 
SYSTEM SUITABILITY TEST PARAMETERS 
 
S.No. Parameters Values in Methanol : Phosphate Buffer (50:50) 
1 Theoretical plates   3090 
2 Tailing factor 1.45 
3 Asymmetric factor 1.71 
4 Capacity factor 0.96 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
TABLE – 23 
OPTICAL CHARACTERISTICS OF ALFUZOSIN HC1 BY  
RP-HPLC METHOD 
 
Parameters Values 
λmax(nm) 245 
Beers law limit (μg/ml) 1-5 
Sandell’s sensitivity (μg/cm2/0.001 A.U) 6.8194E-10 
Molar absorptivity (L mol–1 cm–1) 6.22363E+11 
Correlation coefficient (r) 0.9995 
Regression equation (y=mx+c) Y=1465781.9X -45649.76 
Slope(m) 1465781.9 
Intercept(c) -45649.76 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
TABLE – 24 
QUANTIFICATION OF FORMULATION –ALFOO  
BY RP-HPLC METHOD 
 
 
S.No 
Labeled 
amount 
(mg/tab) 
Amount 
found(mg)
Percentage 
obtained 
 
Average
% 
 
SD %RSD SE 
 
9.86 
 
98.60     
10.06 100.60     
10.09 100.90 99.18 1.2750 1.2855 0.0354
9.80 98.00     
9.80 98.00     
 
1. 
2. 
3. 
4. 
5. 
6. 
 
10.00 
10.00 
10.00 
10.00 
10.00 
10.00 9.90 99.00     
 
 
 
 
 
 
 
 
 
 
   
 TABLE – 25 
RECOVERY STUDIES FOR FORMULATION - ALFOO 
BY RP-HPLC METHOD 
 
S.No 
Amount 
Present 
(µg/ml) 
Amount 
Added 
(µg/ml) 
Amount 
Estimated
(µg/ml) 
Amount 
Recovered
(µg/ml) 
% 
Recovery 
1.484  0.50  1.935  0.451    
 1.513  1.00  2.409  0.895   
 1.513  1.50  3.032  1.518 99.86  
 1.453  2.00  3.351  1.897   
 1.451  2.50  3.962  2.511   
1. 
2. 
3. 
4. 
5. 
6.  1.484  3.00  4.385  2.901   
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